[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Aspen Surgical Products, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":209},{"warningLetters":4,"total":208},[5,31,52,73,94,115,136,153,171,188],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},8,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-07-28T04:00:00Z\">07\u002F28\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-12T04:00:00Z\">06\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fahc-products-inc-728604-06122026\">AHC Products, Inc. \u003C\u002Fa>","Center for Veterinary Medicine","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Michael Wolf\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Compliance Manager and Pharmacist in Charge \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AHC Products, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>301 W Broadway St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Winchester\u003C\u002Fspan>, \u003Cspan>KY\u003C\u002Fspan> \u003Cspan>40391-1915\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 12, 2026\u003C\u002Fp>\u003Cp>CMS Case: 728604\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Wolf:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AHC Products, Inc., located at 301 W Broadway St, Winchester, KY from October 20 to 23, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 351(a)(2)(B)].\u003C\u002Fp>\u003Cp>In addition, this letter concerns your firm’s marketing of several unapproved new animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&amp;C Act). The specific products include \u003Cstrong>(b)(4)\u003C\u002Fstrong>, AniPrin P, and Rot-B-Gone.\u003C\u002Fp>\u003Cp>\u003Cstrong>Current Good Manufacturing Practice Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your November 13, 2025, response to our Form FDA 483 in detail. We have not received any other correspondence from you regarding the inspection.\u003C\u002Fp>\u003Cp>Our review of the evidence gathered during the inspection and your response revealed significant violations, including the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> wound dressing and Animed AniPrin liquid and powder aspirin products (AniPrin LQ and AniPrin P). Your firm failed to ensure that testing and release of drug products for distribution included appropriate laboratory determination of satisfactory conformance to final specifications prior to release. For example, your firm released \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> without conducting any finished product laboratory testing. Your firm's product release decisions for these lots were based solely on visual assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> properties. Additionally, your firm listed test results for microbiological hazards and heavy metal content on Certificates of Analysis (COAs) for all manufactured lots of AniPrin F, AniPrin LQ, AniPrin LQ with Caffeine, and AniPrin P without performing the corresponding analytical testing on the finished product batches.\u003C\u002Fp>\u003Cp>In your response, you stated that for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the methodology utilized for product release was color comparison to the original \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, and you referenced a scientific publication suggesting that \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentration can be reliably estimated by color comparison. You indicated that as part of your investigation, you are investigating a \u003Cstrong>(b)(4)\u003C\u002Fstrong> methodology and have preliminarily confirmed through ICP-MS testing that the finished product was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material. You stated that you are in contact with laboratories to conduct USP testing of the raw material and then validation of methodologies to determine conformance of the finished product to final specifications prior to release.\u003C\u002Fp>\u003Cp>Regarding the AniPrin products, you stated that the heavy metal specifications and microbiological specifications listed on your COAs are controlled using incoming raw material specifications with random verification. You indicated that COAs for aspirin products will be revised to remove these specifications, and COAs for other products will be modified to clarify that these specifications are controlled by incoming specifications with random verification.\u003C\u002Fp>\u003Cp>Your response is inadequate. Visual color comparison is a subjective, qualitative assessment that cannot provide quantitative measurement of active ingredient concentration, as color can be affected by many factors including observer subjectivity. The scientific publication you referenced in the response describes a \u003Cstrong>(b)(4)\u003C\u002Fstrong> method for determining \u003Cstrong>(b)(4)\u003C\u002Fstrong> values in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is an entirely different matrix, application, and analytical purpose than your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. You conducted preliminary ICP-MS testing, but the laboratory report you provided in the response explicitly states that \"the methodology employed was not validated for the matrix\" and that \"the variability of the results are likely from an inconsistent dissociation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and cannot be relied upon to determine a quantitative value for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\"\u003C\u002Fp>\u003Cp>Related to the AniPrin products, your explanation that microbiological and heavy metal specifications are \"controlled using incoming raw material specifications with random verification\" is insufficient, and your proposed corrective action to simply remove these specifications from your Certificates of Analysis or add clarifying language does not address the underlying compliance issue.\u003C\u002Fp>\u003Cp>You are required to establish appropriate and scientifically-sound specifications for your drug products and then to conduct appropriate laboratory testing for conformance to those specifications. See, e.g., 21 CFR 201.22, 211.160, and 211.165.\u003C\u002Fp>\u003Cp>Moreover, your response lacks a definitive timeline for implementing validated analytical methods, provides no plan for verifying the quality of the product lots already distributed to commerce, and does not include a risk assessment for animals that may have received this inadequately tested product.\u003C\u002Fp>\u003Cp>Release testing is a critical safeguard that verifies the identity, strength, quality, and purity of drug product batches before they reach the end-user. Without appropriate testing protocols in place, defective products that could cause harm may fail to be identified and rejected.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>Procedure(s) describing how your firm maintains drug product retains (reserve samples) for each batch manufactured at your facility.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product release testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to ensure that components were suitable for use in the manufacturing of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. For example, you did not perform identity testing on each lot of incoming components including the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> or the inactive ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Adequate testing is essential for establishing that raw materials—including, but not limited to, active pharmaceutical ingredients—conform to the appropriate specifications prior to their use in drug product manufacturing, including identity testing to detect potential mix-ups that occurred before you received the components. As a manufacturer, you bear the responsibility of sampling, testing, and examining drug components before releasing them for use in production to ensure that adequate quality standards are met.\u003C\u002Fp>\u003Cp>Your response stated that you sent samples of the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> along with final product lots for ICP-MS testing and were able to confirm through ICP-MS that the final product was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material. You indicated that you are pursuing USP testing of the raw material with a GMP laboratory, which you expect to be completed within ninety (90) days. You further stated that once you are able to confirm the ability of a GMP laboratory to conduct testing of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material, it will fall under your existing SOP titled \"Quality Testing of Documented Raw Materials.\"\u003C\u002Fp>\u003Cp>Your response is inadequate. The ICP-MS testing you describe was conducted retrospectively, after the raw materials had already been incorporated into finished product that was released and distributed into commerce. You did not describe any interim controls or testing procedures that will be implemented immediately to verify component identity while you establish a relationship with a qualified laboratory. Your response also fails to address the inactive ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>, providing no information about whether identity testing will be performed on these components or whether they will continue to be accepted based solely on supplier COAs.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified;\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality;\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data);\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) to remediate the supplier qualification program and prevent use of unsuitable components, containers and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report, for your third-party laboratory or laboratories conducting your raw material testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to qualify the equipment and to validate the processes used to manufacture your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product batches, prior to their use in commercial production.\u003C\u002Fp>\u003Cp>Multiple lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> agent for wounds, cuts, ulcers, and similar conditions, were released to the market since August 2025 without performing process validation to demonstrate a reproducible commercial manufacturing process that yields a product consistently meeting predetermined specifications and quality attributes.\u003C\u002Fp>\u003Cp>Process validation evaluates the design integrity and state of control of a manufacturing process throughout its lifecycle. Each significant manufacturing stage must be appropriately designed to ensure the quality of inputs, in-process materials, and finished products. Process qualification studies establish whether an initial state of control has been achieved and must be successfully completed before commercial distribution. Ongoing monitoring of process performance and product quality is then required to maintain a stable manufacturing operation over the product lifecycle.\u003C\u002Fp>\u003Cp>You responded that you are investigating the initiation of the manufacturing process of the finished product \u003Cstrong>(b)(4)\u003C\u002Fstrong> without adequate validation as part of deviation PDP-769U. You indicated that validation was initiated, and the management team was retrained on the relevant SOP. Your response states that as part of the validation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> produced since August were tested by ICP-MS to determine the concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, you indicated that with ICP-MS testing, you were able to confirm that the final product was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material.\u003C\u002Fp>\u003Cp>Regarding the equipment qualification, your response was that a deviation (PDP-769U) to SOP PRO-0002.4 Process Change Control has been initiated and that as part of this deviation, you will investigate the implementation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (ID \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Additionally, you indicated that as part of the qualification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to measure the rate of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was purchased to determine the rate of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and a certified thermistor to confirm the temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated that SOP PRO-0002.4 Process Change Control will be revised.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to demonstrate an understanding of process and equipment validation requirements and does not provide a comprehensive plan to validate your manufacturing process or to verify the quality of products already distributed to commerce.\u003C\u002Fp>\u003Cp>The equipment qualification plan included in the response is incomplete. While you state that you have purchased a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and NIST-certified thermistor, merely purchasing measurement instruments does not constitute equipment qualification. You failed to provide a comprehensive qualification protocol to demonstrate that the equipment consistently performs as intended when manufacturing actual product batches.\u003C\u002Fp>\u003Cp>The response did not include a validation protocol that defines for example, the number of validation batches to be manufactured, the sampling plans, the analytical methods to be used with appropriate validation, or the statistical approaches for evaluating process capability.\u003C\u002Fp>\u003Cp>The response addresses only analytical testing of finished products — one component of validation — but fails to address validation of the manufacturing process itself. Using ICP-MS testing on finished product lots as evidence of process validation is scientifically flawed and unacceptable.\u003C\u002Fp>\u003Cp>The ICP-MS results you provided show significant variability, with \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentrations ranging from \u003Cstrong>(b)(4)\u003C\u002Fstrong>% across the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots tested, representing more than \u003Cstrong>(b)(4) \u003C\u002Fstrong>fold difference. This variability demonstrates that your manufacturing process is not in a state of control and raises questions about whether your products consistently meet the labeled claim of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (equivalent to \u003Cstrong>(b)(4)\u003C\u002Fstrong>% available \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Despite this data, your response provides no explanation for this variability, no investigation into the root causes, and no assessment of whether this variability represents actual differences in product composition or limitations of the analytical method.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\u003Cli>A timeline for performing process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control throughout the product lifecycle. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your in-process monitoring and sampling operations, focusing on each upstream process step that can introduce variability. Provide your remediation plan to improve: (1) upstream process controls; (2) in-process detection of variation; and (3) sampling plans.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to follow your written stability testing program (21 CFR 211.166 (a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm has not initiated stability testing to establish appropriate storage conditions and expiration dating for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You manufactured and distributed multiple lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that did not bear an expiration date in the product label.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Furthermore, stability samples for the following drug products were not tested at the required intervals, and no deviation investigation was initiated: (1) AniPrin P, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufacture date \u003Cstrong>(b)(4)\u003C\u002Fstrong>, missed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing which was required on \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and (2) AniPrin LQ 12% Regular Gallon, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufacture date \u003Cstrong>(b)(4)\u003C\u002Fstrong>, missed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing which was required on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This is a repeated observation from the previous inspection conducted in March 2022, where similar deficiencies in your stability program were cited.\u003C\u002Fp>\u003Cp>Stability testing is essential to establish scientifically justified expiration dates and appropriate storage conditions that ensure drug products remain safe and effective from the time of manufacture until the end of their labeled shelf life.\u003C\u002Fp>\u003Cp>Regarding the lack of stability testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your response states that at such time as you are able to establish appropriate testing of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> content of the product, you will add this to your ongoing stability program. You indicated that once you go forward with production, an expiration date will reflect what you find on stability testing the initial lots (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> months, depending on the testing).\u003C\u002Fp>\u003Cp>Regarding the missed stability testing intervals for AniPrin products, you stated that for AniPrin P, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the date the missed \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample was required to be tested should be \u003Cstrong>(b)(4)\u003C\u002Fstrong>, not \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and that the stability samples for this lot were pulled prior to the previous FDA inspection.\u003C\u002Fp>\u003Cp>You indicated that in response to the previous inspection, SOP QUA 00019 was changed to pull an additional two samples so that an extra sample is available if one is damaged, and that a deviation has been initiated. For AniPrin LQ 12% Regular Gallon, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you stated that a \u003Cstrong>(b)(4)\u003C\u002Fstrong> stability sample for this lot was not sent and that a deviation was initiated. You stated that the SOP was updated to include a double check that all samples on the reminder system are included in the laboratory accession form and shipped and that the managers responsible were retrained.\u003C\u002Fp>\u003Cp>Your response is inadequate. The response does not address the lack of expiration dates on distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong> products. It does not describe in detail your stability plan with defined stability conditions, time points, and testing of the appropriate critical quality attributes for drug stability, including but not limited to microbiological and impurity testing. Further, you did not include a comprehensive review of all stability samples to verify that no other missed time points exist and failed to describe how you will verify that your revised procedures are effective in preventing recurrence.\u003C\u002Fp>\u003Cp>The requirement to establish a stability program is not contingent upon your ability to develop analytical methods; rather, you should not manufacture and distribute a drug product until you have the capability to conduct appropriate stability testing.\u003C\u002Fp>\u003Cp>Expiration dating must be based on adequate stability data generated under appropriate storage.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the program to determine if the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003Cli>The current expiry date for your finished drug products.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product stability testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Unapproved New Animal Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on our review of your product labeling, your products are drugs under section 201(g)(1) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. For the reasons described below, these products are unapproved new animal drugs and introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Examples of claims FDA observed on your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>\"\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\"\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>AniPrin P\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>“Aids in relieving minor muscle and joint pain.”\u003C\u002Fli>\u003Cli>“…an aid in reducing fever”\u003C\u002Fli>\u003Cli>“…relief of minor muscle aches… pains in horses.”\u003C\u002Fli>\u003Cli>“…Reproductive Harm…”\u003C\u002Fli>\u003Cli>“...analgesic”\u003C\u002Fli>\u003Cli>“...antipyretic”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Rot-B-Gone\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>“...If redness, irritation,..swelling persist, discontinue use.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are new animal drugs under section 201(v) of the FD&amp;C Act, [21 U.S.C. § 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\u003C\u002Fp>\u003Cp>To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. These products are not approved or index listed by FDA, and therefore, the products are unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>You must correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CVM-483-Responses@fda.hhs.gov. Refer to the CMS Case number 728604 FEI 3002745172 and ATTN: Dayna I. Martínez when replying.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Johnetta Walters, Ph.D.\u003Cbr>Acting Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See also, 21 CFR 211.137.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Michael Wolf\n\nRecipient Title\n\nCompliance Manager and Pharmacist in Charge\n\nAHC Products, Inc.\n\n301 W Broadway St\n\nWinchester, KY 40391-1915\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nJune 12, 2026\nCMS Case: 728604\nWARNING LETTER\nDear Mr. Wolf:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AHC Products, Inc., located at 301 W Broadway St, Winchester, KY from October 20 to 23, 2025.\nThis warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 351(a)(2)(B)].\nIn addition, this letter concerns your firm’s marketing of several unapproved new animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&C Act). The specific products include (b)(4), AniPrin P, and Rot-B-Gone.\nCurrent Good Manufacturing Practice Violations\nWe reviewed your November 13, 2025, response to our Form FDA 483 in detail. We have not received any other correspondence from you regarding the inspection.\nOur review of the evidence gathered during the inspection and your response revealed significant violations, including the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYour firm manufactures drug products, including (b)(4) wound dressing and Animed AniPrin liquid and powder aspirin products (AniPrin LQ and AniPrin P). Your firm failed to ensure that testing and release of drug products for distribution included appropriate laboratory determination of satisfactory conformance to final specifications prior to release. For example, your firm released (b)(4) lots of (b)(4) without conducting any finished product laboratory testing. Your firm's product release decisions for these lots were based solely on visual assessment of (b)(4) properties. Additionally, your firm listed test results for microbiological hazards and heavy metal content on Certificates of Analysis (COAs) for all manufactured lots of AniPrin F, AniPrin LQ, AniPrin LQ with Caffeine, and AniPrin P without performing the corresponding analytical testing on the finished product batches.\nIn your response, you stated that for (b)(4), the methodology utilized for product release was color comparison to the original (b)(4) product, and you referenced a scientific publication suggesting that (b)(4) concentration can be reliably estimated by color comparison. You indicated that as part of your investigation, you are investigating a (b)(4) methodology and have preliminarily confirmed through ICP-MS testing that the finished product was approximately (b)(4)% of the (b)(4) raw material. You stated that you are in contact with laboratories to conduct USP testing of the raw material and then validation of methodologies to determine conformance of the finished product to final specifications prior to release.\nRegarding the AniPrin products, you stated that the heavy metal specifications and microbiological specifications listed on your COAs are controlled using incoming raw material specifications with random verification. You indicated that COAs for aspirin products will be revised to remove these specifications, and COAs for other products will be modified to clarify that these specifications are controlled by incoming specifications with random verification.\nYour response is inadequate. Visual color comparison is a subjective, qualitative assessment that cannot provide quantitative measurement of active ingredient concentration, as color can be affected by many factors including observer subjectivity. The scientific publication you referenced in the response describes a (b)(4) method for determining (b)(4) values in (b)(4), which is an entirely different matrix, application, and analytical purpose than your (b)(4) product. You conducted preliminary ICP-MS testing, but the laboratory report you provided in the response explicitly states that \"the methodology employed was not validated for the matrix\" and that \"the variability of the results are likely from an inconsistent dissociation of the (b)(4) and cannot be relied upon to determine a quantitative value for (b)(4).\"\nRelated to the AniPrin products, your explanation that microbiological and heavy metal specifications are \"controlled using incoming raw material specifications with random verification\" is insufficient, and your proposed corrective action to simply remove these specifications from your Certificates of Analysis or add clarifying language does not address the underlying compliance issue.\nYou are required to establish appropriate and scientifically-sound specifications for your drug products and then to conduct appropriate laboratory testing for conformance to those specifications. See, e.g., 21 CFR 201.22, 211.160, and 211.165.\nMoreover, your response lacks a definitive timeline for implementing validated analytical methods, provides no plan for verifying the quality of the product lots already distributed to commerce, and does not include a risk assessment for animals that may have received this inadequately tested product.\nRelease testing is a critical safeguard that verifies the identity, strength, quality, and purity of drug product batches before they reach the end-user. Without appropriate testing protocols in place, defective products that could cause harm may fail to be identified and rejected.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nProcedure(s) describing how your firm maintains drug product retains (reserve samples) for each batch manufactured at your facility.\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nThe firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product release testing.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)).\nYour firm failed to ensure that components were suitable for use in the manufacturing of your (b)(4) product. For example, you did not perform identity testing on each lot of incoming components including the active ingredient (b)(4) or the inactive ingredients (b)(4).\nAdequate testing is essential for establishing that raw materials—including, but not limited to, active pharmaceutical ingredients—conform to the appropriate specifications prior to their use in drug product manufacturing, including identity testing to detect potential mix-ups that occurred before you received the components. As a manufacturer, you bear the responsibility of sampling, testing, and examining drug components before releasing them for use in production to ensure that adequate quality standards are met.\nYour response stated that you sent samples of the active ingredient (b)(4) along with final product lots for ICP-MS testing and were able to confirm through ICP-MS that the final product was approximately (b)(4)% of the (b)(4) raw material. You indicated that you are pursuing USP testing of the raw material with a GMP laboratory, which you expect to be completed within ninety (90) days. You further stated that once you are able to confirm the ability of a GMP laboratory to conduct testing of the (b)(4) raw material, it will fall under your existing SOP titled \"Quality Testing of Documented Raw Materials.\"\nYour response is inadequate. The ICP-MS testing you describe was conducted retrospectively, after the raw materials had already been incorporated into finished product that was released and distributed into commerce. You did not describe any interim controls or testing procedures that will be implemented immediately to verify component identity while you establish a relationship with a qualified laboratory. Your response also fails to address the inactive ingredients (b)(4), providing no information about whether identity testing will be performed on these components or whether they will continue to be accepted based solely on supplier COAs.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified;\no an assessment of all materials to determine whether they are consistently of acceptable quality;\no a review to ensure assigned expiration or retest dates are appropriate (supported by data);\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\nBased on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) to remediate the supplier qualification program and prevent use of unsuitable components, containers and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nThe firm name, address, and supplier qualification report, for your third-party laboratory or laboratories conducting your raw material testing.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm failed to qualify the equipment and to validate the processes used to manufacture your (b)(4) product batches, prior to their use in commercial production.\nMultiple lots of (b)(4), a (b)(4) agent for wounds, cuts, ulcers, and similar conditions, were released to the market since August 2025 without performing process validation to demonstrate a reproducible commercial manufacturing process that yields a product consistently meeting predetermined specifications and quality attributes.\nProcess validation evaluates the design integrity and state of control of a manufacturing process throughout its lifecycle. Each significant manufacturing stage must be appropriately designed to ensure the quality of inputs, in-process materials, and finished products. Process qualification studies establish whether an initial state of control has been achieved and must be successfully completed before commercial distribution. Ongoing monitoring of process performance and product quality is then required to maintain a stable manufacturing operation over the product lifecycle.\nYou responded that you are investigating the initiation of the manufacturing process of the finished product (b)(4) without adequate validation as part of deviation PDP-769U. You indicated that validation was initiated, and the management team was retrained on the relevant SOP. Your response states that as part of the validation, (b)(4) lots of (b)(4) produced since August were tested by ICP-MS to determine the concentration of (b)(4). Further, you indicated that with ICP-MS testing, you were able to confirm that the final product was approximately (b)(4)% of the (b)(4) raw material.\nRegarding the equipment qualification, your response was that a deviation (PDP-769U) to SOP PRO-0002.4 Process Change Control has been initiated and that as part of this deviation, you will investigate the implementation of the (b)(4) (ID (b)(4)). Additionally, you indicated that as part of the qualification of the (b)(4), a (b)(4) to measure the rate of (b)(4) was purchased to determine the rate of (b)(4), and a certified thermistor to confirm the temperature of (b)(4). You stated that SOP PRO-0002.4 Process Change Control will be revised.\nYour response is inadequate because it fails to demonstrate an understanding of process and equipment validation requirements and does not provide a comprehensive plan to validate your manufacturing process or to verify the quality of products already distributed to commerce.\nThe equipment qualification plan included in the response is incomplete. While you state that you have purchased a (b)(4) and NIST-certified thermistor, merely purchasing measurement instruments does not constitute equipment qualification. You failed to provide a comprehensive qualification protocol to demonstrate that the equipment consistently performs as intended when manufacturing actual product batches.\nThe response did not include a validation protocol that defines for example, the number of validation batches to be manufactured, the sampling plans, the analytical methods to be used with appropriate validation, or the statistical approaches for evaluating process capability.\nThe response addresses only analytical testing of finished products — one component of validation — but fails to address validation of the manufacturing process itself. Using ICP-MS testing on finished product lots as evidence of process validation is scientifically flawed and unacceptable.\nThe ICP-MS results you provided show significant variability, with (b)(4) concentrations ranging from (b)(4)% across the (b)(4) lots tested, representing more than (b)(4) fold difference. This variability demonstrates that your manufacturing process is not in a state of control and raises questions about whether your products consistently meet the labeled claim of (b)(4) (equivalent to (b)(4)% available (b)(4)). Despite this data, your response provides no explanation for this variability, no investigation into the root causes, and no assessment of whether this variability represents actual differences in product composition or limitations of the analytical method.\nIn response to this letter, provide:\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\nA timeline for performing process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control throughout the product lifecycle. Also, include your program for qualification of your equipment and facility.\nA comprehensive, independent assessment of your in-process monitoring and sampling operations, focusing on each upstream process step that can introduce variability. Provide your remediation plan to improve: (1) upstream process controls; (2) in-process detection of variation; and (3) sampling plans.\n4. Your firm failed to follow your written stability testing program (21 CFR 211.166 (a)).\nYour firm has not initiated stability testing to establish appropriate storage conditions and expiration dating for (b)(4). You manufactured and distributed multiple lots of (b)(4) that did not bear an expiration date in the product label.1\nFurthermore, stability samples for the following drug products were not tested at the required intervals, and no deviation investigation was initiated: (1) AniPrin P, Lot (b)(4), manufacture date (b)(4), missed the (b)(4) testing which was required on (b)(4); and (2) AniPrin LQ 12% Regular Gallon, Lot (b)(4), manufacture date (b)(4), missed the (b)(4) testing which was required on (b)(4). This is a repeated observation from the previous inspection conducted in March 2022, where similar deficiencies in your stability program were cited.\nStability testing is essential to establish scientifically justified expiration dates and appropriate storage conditions that ensure drug products remain safe and effective from the time of manufacture until the end of their labeled shelf life.\nRegarding the lack of stability testing for (b)(4), your response states that at such time as you are able to establish appropriate testing of the (b)(4) content of the product, you will add this to your ongoing stability program. You indicated that once you go forward with production, an expiration date will reflect what you find on stability testing the initial lots (e.g., (b)(4) months, depending on the testing).\nRegarding the missed stability testing intervals for AniPrin products, you stated that for AniPrin P, Lot (b)(4), the date the missed (b)(4) sample was required to be tested should be (b)(4), not (b)(4), and that the stability samples for this lot were pulled prior to the previous FDA inspection.\nYou indicated that in response to the previous inspection, SOP QUA 00019 was changed to pull an additional two samples so that an extra sample is available if one is damaged, and that a deviation has been initiated. For AniPrin LQ 12% Regular Gallon, Lot (b)(4), you stated that a (b)(4) stability sample for this lot was not sent and that a deviation was initiated. You stated that the SOP was updated to include a double check that all samples on the reminder system are included in the laboratory accession form and shipped and that the managers responsible were retrained.\nYour response is inadequate. The response does not address the lack of expiration dates on distributed (b)(4) products. It does not describe in detail your stability plan with defined stability conditions, time points, and testing of the appropriate critical quality attributes for drug stability, including but not limited to microbiological and impurity testing. Further, you did not include a comprehensive review of all stability samples to verify that no other missed time points exist and failed to describe how you will verify that your revised procedures are effective in preventing recurrence.\nThe requirement to establish a stability program is not contingent upon your ability to develop analytical methods; rather, you should not manufacture and distribute a drug product until you have the capability to conduct appropriate stability testing.\nExpiration dating must be based on adequate stability data generated under appropriate storage.\nIn response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each (b)(4) to the program to determine if the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint)\no All procedures that describe these and other elements of your remediated stability program.\nThe current expiry date for your finished drug products.\nThe firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product stability testing.\nUnapproved New Animal Drug Violations\nBased on our review of your product labeling, your products are drugs under section 201(g)(1) of the Federal Food Drug and Cosmetic Act (FD&C Act) [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. For the reasons described below, these products are unapproved new animal drugs and introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nExamples of claims FDA observed on your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\n(b)(4)\n\"(b)(4).\"\nAniPrin P\n“Aids in relieving minor muscle and joint pain.”\n“…an aid in reducing fever”\n“…relief of minor muscle aches… pains in horses.”\n“…Reproductive Harm…”\n“...analgesic”\n“...antipyretic”\nRot-B-Gone\n“...If redness, irritation,..swelling persist, discontinue use.”\nYour products are new animal drugs under section 201(v) of the FD&C Act, [21 U.S.C. § 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\nTo be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. These products are not approved or index listed by FDA, and therefore, the products are unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nYou must correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CVM-483-Responses@fda.hhs.gov. Refer to the CMS Case number 728604 FEI 3002745172 and ATTN: Dayna I. Martínez when replying.\nSincerely,\n\u002FS\u002F\nJohnetta Walters, Ph.D.\nActing Director\nDivision of Drug Compliance\nOffice Surveillance and Compliance\nCenter for Veterinary Medicine\n___________________\n1 See also, 21 CFR 211.137.\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","AHC Products, Inc.","ahc-products-inc-728604-06122026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fahc-products-inc-728604-06122026","2026-10-26T08:07:51.4831+00:00","Warning Letter","Issued","2026-07-28","728604","Animal & VeterinaryDrugs","Mr. Michael Wolf","2026-08-19T04:27:41.535+00:00","VIA Electronic Mail","2026-06-12",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},22101,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2026-11-03T05:00:00Z\">11\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-19T04:00:00Z\">08\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnext-medical-products-company-llc-727918-08192026\">Next Medical Products Company, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Julia M. Jacobson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Next Medical Products Company, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>45 Columbia Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Branchburg\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08876\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #727918\u003C\u002Fp>\u003Cp>August 19, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Jacobson:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Branchburg, NJ from November 10, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Clear Image Ultrasound Gel, Clear Image Sterile, non-sterile MediChoice Ultrasound Gel, and Clear Image Singles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received responses from you dated January 2, 2026 and March 19, 2026 (responses), concerning our investigator observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to you on December 10, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures where environmental conditions that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(c). Specifically, “Quality Assurance Environmental Testing” procedure, Number 907-030, Revision 005 is not adequate in that:\u003C\u002Fp>\u003Cp>A. Section 2.0 of this procedure, which states “\u003Cstrong>(b)(4)\u003C\u002Fstrong> will be conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong> on each packaging line. \u003Cstrong>(b)(4)\u003C\u002Fstrong>…” is not adequate. You have not demonstrated or justified why \u003Cstrong>(b)(4)\u003C\u002Fstrong> test result can be negated simply by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, your procedure does not require investigating failed test results nor does it address documenting a justification for the dismissal of the initial failed results. For example, your firm established environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> locations for Lots of Clear Image Ultrasound Gel that were packed in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Environmental sampling was performed by your firm on \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> for bottler dispense nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> dispensing nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong> and were recorded as out of specification for aerobic plate counts of 4,100 and 4,000 Colony Forming Units (CFUs) respectively. Your firm performed re-tests on \u003Cstrong>(b)(4)\u003C\u002Fstrong> that were in specification, but there was no documented justification for the dismissal of the initial data nor was any out of specification investigation performed.&nbsp;\u003C\u002Fp>\u003Cp>B. Your firm’s established worst case locations for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> locations listed in Section 2.0 of this procedure are not based on testing or data such as a bioburden\u003Cstrong>(b)(4)\u003C\u002Fstrong> study. You have not adequately demonstrated that the areas chosen are the worst case in terms of number or variety of organisms.\u003C\u002Fp>\u003Cp>C. Section 2.0 of this procedure, which states “The specified test regimen will be conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong> unless findings are significant, in which case, Management may direct more frequent testing” is not adequate. It fails to define what constitutes significant findings. For example, your firm’s management did not consider directing more frequent testing after September 29, 2025, when the monitoring results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed testing with a result of ≥25,000 CFUs.\u003C\u002Fp>\u003Cp>Your firm’s responses to 1A are not adequate. Your firm states in your responses that you will be implementing a correction to modify SOP 907-030 such that the use of environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> and air plates will only be triggered when and after the final microbial testing indicates that a lot is out of specification and will be used to trace the source of the problem. The requirements to establish environmental monitoring procedures are to ensure control of conditions, periodic inspection of control systems, and documentation and review of results. Only performing environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> and air plates testing after the final microbial testing fails is not adequate.\u003C\u002Fp>\u003Cp>Environmental control testing is crucial in non-sterile gel manufacturing to identify and prevent contamination by objectionable microorganisms, ensuring product safety, and efficacy. It validates that manufacturing environments (air, surfaces, water) are controlled to limit bioburden, preventing microbial degradation or toxins that could harm patients or damage the product's chemical properties.\u003C\u002Fp>\u003Cp>Your firm’s responses to 1B are not adequate. Your firm states the intent was to use the results of the recommended overly conservative sampling plan (worst case locations for environmental sample collection based on the opinion of consultants) and evaluate if this “test and adjust” methodology would have any effect on the finished product since its integrity and safety is assured by the final lot of microbial testing. There was no evidence provided in your responses that the areas chosen by the consultants were the worst case in terms of number or variety of organisms, and the corrective action provided in your responses of only performing environmental testing when the gel fails final lot microbial testing is not sufficient to detect all contaminants.\u003C\u002Fp>\u003Cp>Your firm’s responses to 1C is not adequate. Your firm states that “the fact that there was no change in the frequency of the testing does not indicate that the company failed to follow its own procedures or that such change would have been necessary”. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> had a failing result of &gt;25,000, which is orders of magnitude above your identified acceptable level provided in your Quality Assurance Environmental Testing procedure (Number 907-030 rev. 5, section 2) for Aerobic Plate Count (APC): \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your procedure does not clearly define “significant finding” and you do not justify why this failing result is not significant. This failing result is reasonably considered as a “significant finding” that needs to be investigated where your firm needs to identify the action(s) needed to correct and prevent recurrence of quality problems in the packaging area that can lead to contaminated ultrasound gel.\u003C\u002Fp>\u003Cp>2. Failure to establish procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm failed to adequately establish a Corrective and Preventive Action (CAPA) procedure that addresses all potential quality data sources for evaluation and escalation to CAPAs as needed. Although your “Corrective and Preventive Actions” Number 908-019, Revision 003 states under section 2.0 “any NEXT Medical employee may recommend a corrective or preventive action, or one may be initiated as a result of customer feedback, internal audits, directives from a regulatory agency, risk assessments, Management Review, supplier input, trends in nonconforming material and products, or any information that reveals an adverse effect on product quality and customer service”; it does not list all data sources that your firm is evaluating to determine the need for escalation to a CAPA. As a result, your firm is not initiating CAPAs to investigate the cause of nonconformities of product processes, and other quality problems. For example:\u003C\u002Fp>\u003Cp>A. Your firm documented a consecutive increase in out of specification aerobic plate count for environmental \u003Cstrong>(b)(4)\u003C\u002Fstrong> location taken from the dispense nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for packaging of nonsterile Clear Image Ultrasound Gel in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The aerobic plate counts on sample date \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed for 4,000 Colony Forming Units (CFUs). Your firm performed re-tests on \u003Cstrong>(b)(4)\u003C\u002Fstrong> that were in specification but did not recommend corrective actions for the initial failure or after September 29, 2025 when the monitoring results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> had another failing result of ≥25,000 CFUs. From the time period of August 27, 2025 to October 22, 2025, three lots (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) of Clear Image Ultrasonic gel were packaged in \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, totaling \u003Cstrong>(b)(4)\u003C\u002Fstrong> cases. Corrective and preventive actions were not initiated.\u003C\u002Fp>\u003Cp>B. Procedure 907-030, revision 005 titled “Quality Assurance Environmental Testing” states in section 6.1.12 to “ship via overnight to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for analysis” of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples were collected on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and were not sent to the lab until \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples were tested on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the bottler dispense nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> dispensing nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples failed for aerobic plate counts of 4,100 and 4,000 Colony Forming Units (CFUs). Although this incident was recorded in a note to file dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, corrective and preventive actions were not initiated.\u003C\u002Fp>\u003Cp>Your firm’s responses to FDA-483 observation 2A are not adequate. Your firm states in your responses that the “out of specification results from the environmental testing did not reveal that the materials or finished product had been adversely affected or that it otherwise did not meet specifications”. Your firm has already released non-sterile ultrasound gel that did not meet specifications. Specifically, you have received complaints of unusual odor and cloudiness which you confirmed to be contaminated. In addition, your firm determined in your responses “that the provisions of Section 2 of SOP 908-019, Rev 003 were not applicable and no CAPA was required on that basis” due to an inadequate CAPA procedure. As already noted, your procedure does not adequately identify existing and potential causes of nonconformances in which to investigate, determine and implement corrective and preventive actions. Your firm failed to prevent the recurrence of the same quality issue when the aerobic plate counts on sample date \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed for 4,000 Colony Forming Units (CFUs) and then on September 29, 2025 the monitoring results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> had another failing result of ≥25,000 CFUs.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response to 2B cannot be determined at this time. Your firm plans to update procedure SOP-019 to include process nonconformities as a quality data input for the determination of CAPAs in the future. This will include failure to ship laboratory samples within the designated \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your firm failed to implement “Product Development and Management of Design Changes” procedure, Number 500-004, section 7.1, which states “the process of making a significant change to an existing product involves a number of stages where information is managed in a very controlled environment consisting of inputs, outputs, verification processes and formal design reviews”. For example:\u003C\u002Fp>\u003Cp>A. Your firm introduced a new label insert (artwork \u003Cstrong>(b)(4)\u003C\u002Fstrong>, rev A) between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for your non-sterile gel that added contraindications and listed procedures requiring the use of sterile gel. Your firm characterized this as a marketing reminder processed through your label approval process rather than a design change that requires design verification or validation for the new label; \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches were produced with this insert. However, this change was made as a result of a safety concern connected to the non-sterile gel contamination issue reported by the Center for Disease Control (CDC).\u003C\u002Fp>\u003Cp>B. Your firm performed a design change on your Clear Image Ultrasound Scanning Gel in which a preservative ingredient was replaced and design verification and\u002For validation was not performed. This new preservative was a major formula change from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> (preservative and humectant enhancement). Your new preservative formula change adds a new specific effectiveness against paraburkholderia that was not part of the original formulation that could impact the performance, safety, and effectiveness of the ultrasound gel that would require design verification and\u002For validation before implementation.\u003C\u002Fp>\u003Cp>Your firm’s responses to 3A are not adequate. Your firm states in your response that “although we respectfully disagree with the proposition that the development of labeling materials (including advertising and promotional materials) necessarily constitute a change to a device’s specifications”. In your March 19 response, you included your revised Labels and Labeling Control procedure, SOP 703-001, and Section 2 states “All new or revised labeling shall be evaluated to determine whether the change impacts the device specifications. If the labeling change represents a modification to the device specifications, the change should be handled as a design change to the finished device.” This procedure is inadequate because it only considers a labeling change that impacts device specifications. Change control requirements apply to any change to the device, its labeling or its packaging. Additionally, your firm states in your responses that “NEXT respectfully disagrees with this observation as it appears to not be consistent with the facts as we understand them”. “The issuance of Artwork \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Rev A did not constitute a change to any “purchased, in-process or finished product” and was, instead an example of reminder labeling that did not add or delete any device contraindications or otherwise affect the device’s specifications”. This response is not adequate. Your firm characterized this as a marketing reminder rather than a design change conducted in response to a safety concern and did not evaluate the need for or conduct design verification or validation for the new label, processing it only through your label approval process.\u003C\u002Fp>\u003Cp>Your firm’s responses to 3B are not adequate. We acknowledge the additional testing you’re performing of the gel to verify it still meets specifications; however, your response is inadequate in that you have not demonstrated that the “change in preservative did not affect the gel’s mechanical properties or performance specifications”. The new preservative formula is a major formula change from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> which adds a new specific effectiveness against paraburkholderia that was not part of the original formulation that could impact the performance, safety, and effectiveness of the ultrasound gel that would require design verification and\u002For validation before implementation. Even though sterility may not be required, your firm must limit the number of organisms in the non-sterile Ultrasound gel throughout its shelf life.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Ultrasound Scanning Gel, distributed under the brand names Clear Image and MediChoice are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your firm found and CDC confirmed that certain lots of your Clear Image and MediChoice Ultrasound Scanning Gels were contaminated with Paraburkholderia. You sent customer letters and made calls using your firm’s telephone script on 07\u002F23\u002F2025, to inform customers and offer \"free replacement\" or \"disposal directions\". CDRH’s clinical review concludes that use of the contaminated gel may present a risk to health. This action is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of 12\u002F10\u002F2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. You have not submitted a Report of Correction or Removal to FDA as of August 13, 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that the Ultrasound Scanning Gel, distributed under the brand names Clear Image and MediChoice, is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Specifically, the Clear Image Ultrasound Scanning Gel was cleared under K883917 as a coupling agent during ultrasound procedures to eliminate air between transducer surface and skin to facilitate imaging. Your firm changed the preservative in the subject ultrasound gel formulation from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in 2024, which is considered a modification in material formulation that could significantly affect the device's safety or effectiveness. These changes thus require a 510(k) as provided in 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>The change could affect the device’s biocompatibility, stability, sterility and shelf life. As described here, the new preservative, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (which contains \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>), represents a change in the chemical profile compared to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and therefore the biocompatibility must be re-evaluated. Your firm must ensure that the new preservative maintains the same preservative effectiveness, stability, sterility and shelf-life claims as previously cleared. The repeat biocompatibility testing, preservative effectiveness, shelf life, and stability should be reviewed in a new 510(k) by the Agency. The firm must demonstrate that the number of organisms in the subject ultrasound gel is limited throughout its shelf life.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on November 10, 2025, through December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727918” when replying. If you have any questions about the contents of this letter, please contact: Robert Maffei, Compliance Officer at Robert.Maffei@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMs. Julia M. Jacobson\n\nRecipient Title\n\nPresident and CEO\n\nNext Medical Products Company, LLC\n\n45 Columbia Road\n\nBranchburg, NJ 08876\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #727918\nAugust 19, 2026\nDear Ms. Jacobson:\nDuring an inspection of your firm located in Branchburg, NJ from November 10, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Clear Image Ultrasound Gel, Clear Image Sterile, non-sterile MediChoice Ultrasound Gel, and Clear Image Singles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from you dated January 2, 2026 and March 19, 2026 (responses), concerning our investigator observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to you on December 10, 2025. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures where environmental conditions that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(c). Specifically, “Quality Assurance Environmental Testing” procedure, Number 907-030, Revision 005 is not adequate in that:\nA. Section 2.0 of this procedure, which states “(b)(4) will be conducted (b)(4) on each packaging line. (b)(4)…” is not adequate. You have not demonstrated or justified why (b)(4) test result can be negated simply by (b)(4). Further, your procedure does not require investigating failed test results nor does it address documenting a justification for the dismissal of the initial failed results. For example, your firm established environmental (b)(4) locations for Lots of Clear Image Ultrasound Gel that were packed in (b)(4). Environmental sampling was performed by your firm on (b)(4) for (b)(4) for bottler dispense nozzle (b)(4) and (b)(4) dispensing nozzle (b)(4) and were recorded as out of specification for aerobic plate counts of 4,100 and 4,000 Colony Forming Units (CFUs) respectively. Your firm performed re-tests on (b)(4) that were in specification, but there was no documented justification for the dismissal of the initial data nor was any out of specification investigation performed.\nB. Your firm’s established worst case locations for the (b)(4) locations listed in Section 2.0 of this procedure are not based on testing or data such as a bioburden(b)(4) study. You have not adequately demonstrated that the areas chosen are the worst case in terms of number or variety of organisms.\nC. Section 2.0 of this procedure, which states “The specified test regimen will be conducted (b)(4) unless findings are significant, in which case, Management may direct more frequent testing” is not adequate. It fails to define what constitutes significant findings. For example, your firm’s management did not consider directing more frequent testing after September 29, 2025, when the monitoring results for the (b)(4) failed testing with a result of ≥25,000 CFUs.\nYour firm’s responses to 1A are not adequate. Your firm states in your responses that you will be implementing a correction to modify SOP 907-030 such that the use of environmental (b)(4) and air plates will only be triggered when and after the final microbial testing indicates that a lot is out of specification and will be used to trace the source of the problem. The requirements to establish environmental monitoring procedures are to ensure control of conditions, periodic inspection of control systems, and documentation and review of results. Only performing environmental (b)(4) and air plates testing after the final microbial testing fails is not adequate.\nEnvironmental control testing is crucial in non-sterile gel manufacturing to identify and prevent contamination by objectionable microorganisms, ensuring product safety, and efficacy. It validates that manufacturing environments (air, surfaces, water) are controlled to limit bioburden, preventing microbial degradation or toxins that could harm patients or damage the product's chemical properties.\nYour firm’s responses to 1B are not adequate. Your firm states the intent was to use the results of the recommended overly conservative sampling plan (worst case locations for environmental sample collection based on the opinion of consultants) and evaluate if this “test and adjust” methodology would have any effect on the finished product since its integrity and safety is assured by the final lot of microbial testing. There was no evidence provided in your responses that the areas chosen by the consultants were the worst case in terms of number or variety of organisms, and the corrective action provided in your responses of only performing environmental testing when the gel fails final lot microbial testing is not sufficient to detect all contaminants.\nYour firm’s responses to 1C is not adequate. Your firm states that “the fact that there was no change in the frequency of the testing does not indicate that the company failed to follow its own procedures or that such change would have been necessary”. The (b)(4) monitoring results for the (b)(4) had a failing result of >25,000, which is orders of magnitude above your identified acceptable level provided in your Quality Assurance Environmental Testing procedure (Number 907-030 rev. 5, section 2) for Aerobic Plate Count (APC): (b)(4). Your procedure does not clearly define “significant finding” and you do not justify why this failing result is not significant. This failing result is reasonably considered as a “significant finding” that needs to be investigated where your firm needs to identify the action(s) needed to correct and prevent recurrence of quality problems in the packaging area that can lead to contaminated ultrasound gel.\n2. Failure to establish procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm failed to adequately establish a Corrective and Preventive Action (CAPA) procedure that addresses all potential quality data sources for evaluation and escalation to CAPAs as needed. Although your “Corrective and Preventive Actions” Number 908-019, Revision 003 states under section 2.0 “any NEXT Medical employee may recommend a corrective or preventive action, or one may be initiated as a result of customer feedback, internal audits, directives from a regulatory agency, risk assessments, Management Review, supplier input, trends in nonconforming material and products, or any information that reveals an adverse effect on product quality and customer service”; it does not list all data sources that your firm is evaluating to determine the need for escalation to a CAPA. As a result, your firm is not initiating CAPAs to investigate the cause of nonconformities of product processes, and other quality problems. For example:\nA. Your firm documented a consecutive increase in out of specification aerobic plate count for environmental (b)(4) location taken from the dispense nozzle (b)(4) used for packaging of nonsterile Clear Image Ultrasound Gel in (b)(4). The aerobic plate counts on sample date (b)(4) for (b)(4) failed for 4,000 Colony Forming Units (CFUs). Your firm performed re-tests on (b)(4) that were in specification but did not recommend corrective actions for the initial failure or after September 29, 2025 when the monitoring results for the (b)(4) had another failing result of ≥25,000 CFUs. From the time period of August 27, 2025 to October 22, 2025, three lots ((b)(4)) of Clear Image Ultrasonic gel were packaged in (b)(4) with (b)(4), totaling (b)(4) cases. Corrective and preventive actions were not initiated.\nB. Procedure 907-030, revision 005 titled “Quality Assurance Environmental Testing” states in section 6.1.12 to “ship via overnight to (b)(4) for analysis” of the (b)(4). (b)(4) samples were collected on (b)(4) and were not sent to the lab until (b)(4). These (b)(4) samples were tested on (b)(4) and (b)(4) and the bottler dispense nozzle (b)(4), and the (b)(4) dispensing nozzle (b)(4) samples failed for aerobic plate counts of 4,100 and 4,000 Colony Forming Units (CFUs). Although this incident was recorded in a note to file dated (b)(4), corrective and preventive actions were not initiated.\nYour firm’s responses to FDA-483 observation 2A are not adequate. Your firm states in your responses that the “out of specification results from the environmental testing did not reveal that the materials or finished product had been adversely affected or that it otherwise did not meet specifications”. Your firm has already released non-sterile ultrasound gel that did not meet specifications. Specifically, you have received complaints of unusual odor and cloudiness which you confirmed to be contaminated. In addition, your firm determined in your responses “that the provisions of Section 2 of SOP 908-019, Rev 003 were not applicable and no CAPA was required on that basis” due to an inadequate CAPA procedure. As already noted, your procedure does not adequately identify existing and potential causes of nonconformances in which to investigate, determine and implement corrective and preventive actions. Your firm failed to prevent the recurrence of the same quality issue when the aerobic plate counts on sample date (b)(4) for (b)(4) failed for 4,000 Colony Forming Units (CFUs) and then on September 29, 2025 the monitoring results for the (b)(4) had another failing result of ≥25,000 CFUs.\nThe adequacy of your firm’s response to 2B cannot be determined at this time. Your firm plans to update procedure SOP-019 to include process nonconformities as a quality data input for the determination of CAPAs in the future. This will include failure to ship laboratory samples within the designated (b)(4).\n3. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your firm failed to implement “Product Development and Management of Design Changes” procedure, Number 500-004, section 7.1, which states “the process of making a significant change to an existing product involves a number of stages where information is managed in a very controlled environment consisting of inputs, outputs, verification processes and formal design reviews”. For example:\nA. Your firm introduced a new label insert (artwork (b)(4), rev A) between (b)(4) and (b)(4) for your non-sterile gel that added contraindications and listed procedures requiring the use of sterile gel. Your firm characterized this as a marketing reminder processed through your label approval process rather than a design change that requires design verification or validation for the new label; (b)(4) batches were produced with this insert. However, this change was made as a result of a safety concern connected to the non-sterile gel contamination issue reported by the Center for Disease Control (CDC).\nB. Your firm performed a design change on your Clear Image Ultrasound Scanning Gel in which a preservative ingredient was replaced and design verification and\u002For validation was not performed. This new preservative was a major formula change from (b)(4) to (b)(4) (preservative and humectant enhancement). Your new preservative formula change adds a new specific effectiveness against paraburkholderia that was not part of the original formulation that could impact the performance, safety, and effectiveness of the ultrasound gel that would require design verification and\u002For validation before implementation.\nYour firm’s responses to 3A are not adequate. Your firm states in your response that “although we respectfully disagree with the proposition that the development of labeling materials (including advertising and promotional materials) necessarily constitute a change to a device’s specifications”. In your March 19 response, you included your revised Labels and Labeling Control procedure, SOP 703-001, and Section 2 states “All new or revised labeling shall be evaluated to determine whether the change impacts the device specifications. If the labeling change represents a modification to the device specifications, the change should be handled as a design change to the finished device.” This procedure is inadequate because it only considers a labeling change that impacts device specifications. Change control requirements apply to any change to the device, its labeling or its packaging. Additionally, your firm states in your responses that “NEXT respectfully disagrees with this observation as it appears to not be consistent with the facts as we understand them”. “The issuance of Artwork (b)(4), Rev A did not constitute a change to any “purchased, in-process or finished product” and was, instead an example of reminder labeling that did not add or delete any device contraindications or otherwise affect the device’s specifications”. This response is not adequate. Your firm characterized this as a marketing reminder rather than a design change conducted in response to a safety concern and did not evaluate the need for or conduct design verification or validation for the new label, processing it only through your label approval process.\nYour firm’s responses to 3B are not adequate. We acknowledge the additional testing you’re performing of the gel to verify it still meets specifications; however, your response is inadequate in that you have not demonstrated that the “change in preservative did not affect the gel’s mechanical properties or performance specifications”. The new preservative formula is a major formula change from (b)(4) to (b)(4) which adds a new specific effectiveness against paraburkholderia that was not part of the original formulation that could impact the performance, safety, and effectiveness of the ultrasound gel that would require design verification and\u002For validation before implementation. Even though sterility may not be required, your firm must limit the number of organisms in the non-sterile Ultrasound gel throughout its shelf life.\nCorrections and Removals Violation\nOur inspection also revealed that your firm’s Ultrasound Scanning Gel, distributed under the brand names Clear Image and MediChoice are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your firm found and CDC confirmed that certain lots of your Clear Image and MediChoice Ultrasound Scanning Gels were contaminated with Paraburkholderia. You sent customer letters and made calls using your firm’s telephone script on 07\u002F23\u002F2025, to inform customers and offer \"free replacement\" or \"disposal directions\". CDRH’s clinical review concludes that use of the contaminated gel may present a risk to health. This action is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of 12\u002F10\u002F2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\nYour firm’s responses are not adequate. You have not submitted a Report of Correction or Removal to FDA as of August 13, 2026.\nUnapproved Device Violation\nOur inspection also revealed that the Ultrasound Scanning Gel, distributed under the brand names Clear Image and MediChoice, is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nSpecifically, the Clear Image Ultrasound Scanning Gel was cleared under K883917 as a coupling agent during ultrasound procedures to eliminate air between transducer surface and skin to facilitate imaging. Your firm changed the preservative in the subject ultrasound gel formulation from (b)(4) to (b)(4) in 2024, which is considered a modification in material formulation that could significantly affect the device's safety or effectiveness. These changes thus require a 510(k) as provided in 21 CFR 807.81(a)(3)(i).\nThe change could affect the device’s biocompatibility, stability, sterility and shelf life. As described here, the new preservative, (b)(4) (which contains (b)(4) and (b)(4)), represents a change in the chemical profile compared to (b)(4), and therefore the biocompatibility must be re-evaluated. Your firm must ensure that the new preservative maintains the same preservative effectiveness, stability, sterility and shelf-life claims as previously cleared. The repeat biocompatibility testing, preservative effectiveness, shelf life, and stability should be reviewed in a new 510(k) by the Agency. The firm must demonstrate that the number of organisms in the subject ultrasound gel is limited throughout its shelf life.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on November 10, 2025, through December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727918” when replying. If you have any questions about the contents of this letter, please contact: Robert Maffei, Compliance Officer at Robert.Maffei@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Next Medical Products Company, LLC","next-medical-products-company-llc-727918-08192026","2026-11-10T01:02:16.121874+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnext-medical-products-company-llc-727918-08192026","2026-11-17T01:02:03.701861+00:00","2026-11-03","727918","Medical Devices","Ms. Julia M. Jacobson","2026-11-10T01:03:13.668+00:00","2026-08-19",{"id":53,"raw":54,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":11,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},684,[55,56,57,11,58,13,13,13],"\u003Ctime datetime=\"2025-09-02T04:00:00Z\">09\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-16T04:00:00Z\">07\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynergy-animal-products-inc-712860-07162025\">Synergy Animal Products, Inc. \u003C\u002Fa>","Unapproved New Animal Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mark A. Hassler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Synergy Animal Products, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1681 Schubert Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bethel\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19507\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:synergyanimalproducts@gmail.com\"> synergyanimalproducts@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>July 16, 2025\u003C\u002Fp>\u003Cp>Re: 712860\u003C\u002Fp>\u003Cp>Dear Mark A. Hassler,\u003C\u002Fp>\u003Cp>This letter concerns your firm’s marketing of adulterated and misbranded animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&amp;C Act).\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your facility located at 1681 Schubert Rd, Bethel, PA 19507 from September 5, 2024, through September 10, 2024. After a review of the inspection report, and a subsequent review of your website, synergyanimalproducts.com, we have determined that you are marketing drugs for use in animals. Specifically, your website and product labeling establish that your, Ex-Cell Countdown 7000, Natural Cow Herbal Support, Ex-Cell Somaticare, Superior Cow Cream, and Super Cow Udder Mint products are drugs under section 201(g)(1) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of animals. For the reasons discussed below, these products are unapproved new animal drugs. Introducing or delivering these unapproved new animal drugs for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>This Warning Letter also summarizes violations related to the FD&amp;C Act’s labeling requirements for drugs. You distribute drugs that are misbranded under section 502(f)(1) of the FD&amp;C Act, [21 U.S.C. § 352(f)(1)] because their labeling lacks adequate directions for use.\u003C\u002Fp>\u003Cp>This Warning Letter also summarizes violations of the FD&amp;C Act’s drug manufacturer registration and listing requirements. You do not comply with sections 510(b) and (j) of the FD&amp;C Act [21 U.S.C. § 360(b), (j)] related to drug manufacturer registration and drug listing, and therefore the drugs you distribute are misbranded under section 502(o) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>This Warning Letter also summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), Parts 210 and 211. Because your methods, facilities or controls for manufacturing, processing, packing or holding drugs do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, [21 U.S.C. § 351(a)(2)(B)].\u003C\u002Fp>\u003Cp>You can find the FD&amp;C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\u003Cp>We reviewed your September 28, 2024, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Animal Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Examples of claims FDA observed on your website, synergyanimalproducts.com, and your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>• \u003Cstrong>Ex-Cell Countdown 7000\u003C\u002Fstrong>\u003Cbr>o “Ex-cell Countdown 7000 is a broad coverage product that is great when you’re unsure of the problem you are having, as well as stringiness and hard quarters.”\u003Cbr>o From your ‘Most Common Recommendations’ infographic:\u003Cbr> “White or Yellow Chunks”\u003Cbr> “High SCC or No Visible Signs”\u003Cbr> “Stringy or Hard Quarter”\u003Cbr> “Thick Consistency”\u003C\u002Fp>\u003Cp>• \u003Cstrong>Natural Cow Herbal Support\u003C\u002Fstrong>\u003Cbr>o “Use for…high somatic cell count, scours…”\u003Cbr>o “Scours in Calves”\u003Cbr>o “High Somatic Cell”\u003Cbr>o “… because of their anti-septic, anti-inflammatory &amp; antibacterial properties.”\u003C\u002Fp>\u003Cp>• \u003Cstrong>Ex-Cell Somaticare\u003C\u002Fstrong>\u003Cbr>o “Use when problems look clear and watery and\u002For may contain flakes.”\u003Cbr>o “This formula is designed to target problems that look clear and watery and\u002For may contain flakes”\u003C\u002Fp>\u003Cp>• \u003Cstrong>Superior Cow Cream\u003C\u002Fstrong>\u003Cbr>o “… Sore Teats – Flaky Milk – High S.C.C”\u003Cbr>o “…works beneath the skins surface at a deeper level than traditional udder creams.”\u003C\u002Fp>\u003Cp>• \u003Cstrong>Super Cow Udder Mint\u003C\u002Fstrong>\u003Cbr>o “Super Cow Udder Mint is not for every mastitis case. In most cases, Superior Cow Cream will work, but if a case is really bad, you want the stronger Super Cow Udder Mint.”\u003Cbr>o “… Sore Teats – Flaky Milk – High Somatic Cell Count”\u003C\u002Fp>\u003Cp>Because your products are intended to diagnose, cure, mitigate, treat, or prevent disease and\u002For intended to affect the structure or any function of the body of animals, they are drugs within the meaning of section 201(g)(1) of the FD&amp;C Act, [21 U.S.C. § 321 (g)(1)]. These products are new animal drugs under section 201(v) of the FD&amp;C Act, [21 U.S.C. 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, new animal drugs must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. The new animal drugs you market are not approved or index listed by FDA, and therefore they are unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act, [21 U.S.C. § 351(a)(5)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>Drugs Without Adequate Directions for Use\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You distribute drugs that are misbranded under section 502(f)(1) of the FD&amp;C Act, [21 U.S.C. § 352(f)(1)] because their labeling lacks adequate directions for use. Adequate directions for use include, among other things, statements of all intended uses (indications), routes of administration, and frequency of administration in language understandable by laypersons. 21 CFR 201.5.\u003C\u002Fp>\u003Cp>Your website states: “Q: What are your products used for? A: Our products are a natural support system for dairy animals udder health. Our products are not FDA approved; therefore we cannot make any claims regarding our products’ purpose. It is at the farmers discretion to determine the products use.”\u003C\u002Fp>\u003Cp>Your attempt to avoid making claims about your products’ uses put animals (and the humans who might consume the byproducts of the dairy cows treated with your products) at risk by not giving users adequate directions for safe use of your drugs. You market your products for use by the general public (laypersons)–who do not know the details of your products’ formulations and how to safely use them–unless you provide that information in the product’s labeling. Although your products are unapproved, they are drugs and must therefore bear adequate directions for use, including statements of their intended uses that are understandable by laypersons.\u003C\u002Fp>\u003Cp>For example, with respect to your products’ labeling, (including its labels and the labeling on your website):\u003C\u002Fp>\u003Cp>- \u003Cstrong>Ex-Cell Countdown 7000\u003C\u002Fstrong> does not have a clear indication statement that is understandable by laypersons (e.g., vague language such as “great when you’re unsure of the problem you are having”,” “stringiness,” and other statements that laypersons may not understand, such as “high S.C.C.”). This product is also missing clear directions on the route of administration.\u003C\u002Fp>\u003Cp>- “\u003Cstrong>Natural Cow Herbal Support\u003C\u002Fstrong>” does not have a clear indication statement that is understandable by laypersons (e.g., use of terminology not familiar to laypersons such as, “High Somatic Cell,” and vague language such as “Irregular milk”).\u003C\u002Fp>\u003Cp>- \u003Cstrong>Ex-Cell Somaticare\u003C\u002Fstrong> does not have a clear indication statement that is understandable by laypersons (e.g., vague language such as “when problems look clear and watery”) and has no directions indicating how to prepare the product for administration.\u003C\u002Fp>\u003Cp>- \u003Cstrong>Superior Cow Cream\u003C\u002Fstrong> does not have a clear indication statement that is understandable by laypersons (“e.g., vague statements such as “Flaky Milk” and terminology not appropriate for laypersons, such as “High S.C.C”) and its labeling contains contradictory directions for frequency of use (1 to 2 fl. oz. after milking for 2 to 5 days as needed, per the label vs. twice a day for 6-10 days, per the labeling on the product’s website at synergyanimalproducts.com).\u003C\u002Fp>\u003Cp>- \u003Cstrong>Super Cow Udder Mint\u003C\u002Fstrong> does not have a clear indication statement that is understandable by laypersons (e.g., use of terminology not familiar to laypersons, such as “High Somatic Cell Count,” and vague language such as “Flaky Milk”).\u003C\u002Fp>\u003Cp>During our review, we noted many other products you sell appear to have similar issues. You should review them all to ensure they contain adequate directions for use.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Drug Registration and Listing Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Sections 510(b) and (j) of the FD&amp;C Act [21 U.S.C. § 360(b), (j)] require that manufacturers of drugs, including animal drugs, register their manufacturing establishments with FDA and provide the agency with a list of all the drugs they manufacture. Drugs that are manufactured in unregistered establishments or that have not been listed with FDA are misbranded under section 502(o) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>None of the animal drugs you manufacture are listed with FDA, nor have they been manufactured in a facility that is registered with FDA. Accordingly, these animal drugs are misbranded. Introduction or delivery for introduction of a misbranded animal drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Current Good Manufacturing Practice Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the evidence gathered during our inspection, we have determined your firm’s operations are out of compliance with the FD&amp;C Act’s Current Good Manufacturing Practice (CGMP) requirements (section 501(a)(2)(B) of the FD&amp;C Act, [21 U.S.C. § 351(a)(2)(B)]), and the requirements of its implementing regulation for drug products, 21 CFR Parts 210 and 211. Our inspection found that your operations were fundamentally noncompliant with CGMP in that you had no quality unit, had no written procedures applicable to the production and distribution of animal drug products, performed no testing, and kept no records pertaining to the manufacturing of these products.\u003C\u002Fp>\u003Cp>Your failure to manufacture drugs in accordance with CGMP means there is no assurance they meet the safety requirements of the FD&amp;C Act or have the identity and strength, and meet the quality and purity characteristics, which they are represented to possess. Moreover, as you manufacture drugs for use in food-producing animals (dairy cows), your inadequate controls increase the risk that your drugs will inadvertently enter the food supply.\u003C\u002Fp>\u003Cp>During the most recent FDA inspection of your facility, our investigators observed specific CGMP violations, including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1) Failure to establish a quality control unit. (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm has no quality unit (QU) or any procedures for the responsibilities of a QU (including\u002Fbut not limited to setting specifications, performing investigations, reviewing complaints, reviewing production records, conducting annual product reviews, and approving or rejecting procedures, components, labeling, and drug products). During the inspection, you stated you did not consider your products to be animal drugs and therefore you did not establish any CGMP procedures. For the reasons discussed earlier in this letter, your products are animal drugs and are therefore subject to the CGMP requirement. A functioning quality unit with approval and rejection authority is a core element of CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>2) Failure to test your drug products for conformance to final specifications. (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>No release testing was conducted on any animal drug products you manufactured and distributed. Testing each batch of drug products for conformance to specifications, including the identity and strength of each active ingredient, is important to ensure your drugs have the quantity of active ingredient you believe is needed to perform as you intend.\u003C\u002Fp>\u003Cp>\u003Cstrong>3) Failure to test your incoming components for identity, purity, strength, and other appropriate quality attributes. (21 CFR 211.84(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not perform specific identity testing for each shipment of each lot of each component you receive and then test each component for conformity with all appropriate written specifications or otherwise establish the reliability of the supplier’s analyses.\u003C\u002Fp>\u003Cp>The quality of the components you use has a direct effect on the quality of the drug products you manufacture, and testing incoming components for identity is an important step in preventing mislabeled components from being used in manufacturing.\u003C\u002Fp>\u003Cp>Additionally, you do not have written procedures pertaining to incoming components or any associated records including, but not limited to: written procedures related to the receiving of containers, closures, and components; the rejection of nonconforming materials; or supplier qualifications\u002Fsupplier quality agreements. You do not maintain copies of your supplier’s test results (i.e. Certificates of Analysis) for each raw material you use. You use raw materials from multiple outside suppliers.\u003C\u002Fp>\u003Cp>\u003Cstrong>4) Failure to establish written procedures for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product. (21 CFR 211.67).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, we observed visibly dirty equipment (e.g., your \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank) that you use to manufacture your drug products.\u003C\u002Fp>\u003Cp>You do not have any written procedures or records for the cleaning and maintenance of equipment that you use to make animal drugs. This includes, but is not limited to: written procedures for cleaning, equipment cleaning validation studies, clean\u002Fdirty hold time studies, and cleaning logs. You also do not have preventative maintenance procedures and maintenance logs.\u003C\u002Fp>\u003Cp>Properly cleaned and maintained equipment is needed to prevent microbiological contamination or cross-contamination between batches of different drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>5) Failure to establish master production and control records for each drug product. (21 CFR 211.186(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not have master production and control records for any of the drugs you produce. These documents are the foundation of manufacturing in compliance with CGMP because they describe and define each drug, its formulation, the containers, closures, and labeling to be used, the manufacturing process to be followed (the equipment and process), and the sampling and testing to be performed, among other things. As of the inspection, you did not have formulas for any of your products in writing or any master records of any type. These master records are a basic CGMP requirement and necessary to ensure consistency between batches of drug product.\u003C\u002Fp>\u003Cp>\u003Cstrong>6) Failure to prepare batch production and control records for each batch of drug product produced. (21 CFR 211.188).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not keep any written records (i.e., batch records) to document your manufacturing process.\u003C\u002Fp>\u003Cp>Batch records are critical for a variety of reasons, such as facilitating review of the production process before batch release, performing investigations, and performing recalls. You have no records to establish what lots of what components were used, how much of each component was actually added, or what manufacturing processes were performed, and you would be unable to evaluate the need for a recall if, for example, there was a recall on a lot of one of the components you used.\u003C\u002Fp>\u003Cp>In summary, you violate the FD&amp;C Act’s CGMP requirement by:\u003Cbr>- using untested components from suppliers you did not qualify; (\u003Cstrong>violation 3 above\u003C\u002Fstrong>)\u003Cbr>- to manufacture drugs with no defined process or written formulation (i.e., no master production record); (\u003Cstrong>violation 5 above\u003C\u002Fstrong>)\u003Cbr>- using equipment which we observed to be unclean during our inspection and for which you do not have cleaning procedures; (\u003Cstrong>violation 4 above\u003C\u002Fstrong>)\u003Cbr>- without keeping any written records of what components or equipment you used (i.e., no batch records); (\u003Cstrong>violation 6 above\u003C\u002Fstrong>)\u003Cbr>- without performing any tests to verify the quality of the finished product (e.g., identity and strength of active ingredient); (\u003Cstrong>violation 2 above\u003C\u002Fstrong>)\u003Cbr>- and then released the drugs without the oversight of a quality unit, which should have rejected those drugs for the reasons above. (\u003Cstrong>violation 1 above\u003C\u002Fstrong>)\u003C\u002Fp>\u003Cp>We have considered your response to the Form FDA 483. You acknowledged our concern about the absence of an adequately established quality unit and committed to the establishment of a dedicated QU by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response failed to provide adequate detail and timelines regarding implementation. We are concerned that your complete lack of a quality unit has contributed–and continues to contribute–to a total failure of oversight regarding your CGMP operations. FDA has not received any recent updates from your firm regarding your proposed corrective actions. Additionally, your responses do not consider the need to mitigate any potential risks that may be associated with your CGMP-deficient processes in relation to your distributed products. During the inspection, you acknowledged the conditions cited above generally apply to all drugs you have manufactured since 2017.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and effectiveness of corrective actions and preventive actions. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Conclusion\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. Our review indicates that you are offering for sale unapproved new animal drugs in addition to those listed above. If FDA takes legal action, the action may address all of your unapproved drugs, not just those listed above. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please direct your response to the U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “Reference 712860” in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Cindy L. Burnsteel, DVM\u003Cbr>Acting Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>Cc: info@synergyanimalproducts.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\n\nRecipient:\n\nRecipient Name\n\nMark A. Hassler\n\nRecipient Title\n\nPresident and CEO\n\nSynergy Animal Products, Inc.\n\n1681 Schubert Rd\n\nBethel, PA 19507\n\nUnited States\n\nsynergyanimalproducts@gmail.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nJuly 16, 2025\nRe: 712860\nDear Mark A. Hassler,\nThis letter concerns your firm’s marketing of adulterated and misbranded animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&C Act).\nThe U.S. Food and Drug Administration (FDA) inspected your facility located at 1681 Schubert Rd, Bethel, PA 19507 from September 5, 2024, through September 10, 2024. After a review of the inspection report, and a subsequent review of your website, synergyanimalproducts.com, we have determined that you are marketing drugs for use in animals. Specifically, your website and product labeling establish that your, Ex-Cell Countdown 7000, Natural Cow Herbal Support, Ex-Cell Somaticare, Superior Cow Cream, and Super Cow Udder Mint products are drugs under section 201(g)(1) of the FD&C Act [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of animals. For the reasons discussed below, these products are unapproved new animal drugs. Introducing or delivering these unapproved new animal drugs for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nThis Warning Letter also summarizes violations related to the FD&C Act’s labeling requirements for drugs. You distribute drugs that are misbranded under section 502(f)(1) of the FD&C Act, [21 U.S.C. § 352(f)(1)] because their labeling lacks adequate directions for use.\nThis Warning Letter also summarizes violations of the FD&C Act’s drug manufacturer registration and listing requirements. You do not comply with sections 510(b) and (j) of the FD&C Act [21 U.S.C. § 360(b), (j)] related to drug manufacturer registration and drug listing, and therefore the drugs you distribute are misbranded under section 502(o) of the FD&C Act.\nThis Warning Letter also summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), Parts 210 and 211. Because your methods, facilities or controls for manufacturing, processing, packing or holding drugs do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, [21 U.S.C. § 351(a)(2)(B)].\nYou can find the FD&C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\nWe reviewed your September 28, 2024, response to our Form FDA 483 in detail.\nUnapproved New Animal Drug Violations\nExamples of claims FDA observed on your website, synergyanimalproducts.com, and your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\n• Ex-Cell Countdown 7000\no “Ex-cell Countdown 7000 is a broad coverage product that is great when you’re unsure of the problem you are having, as well as stringiness and hard quarters.”\no From your ‘Most Common Recommendations’ infographic:\n “White or Yellow Chunks”\n “High SCC or No Visible Signs”\n “Stringy or Hard Quarter”\n “Thick Consistency”\n• Natural Cow Herbal Support\no “Use for…high somatic cell count, scours…”\no “Scours in Calves”\no “High Somatic Cell”\no “… because of their anti-septic, anti-inflammatory & antibacterial properties.”\n• Ex-Cell Somaticare\no “Use when problems look clear and watery and\u002For may contain flakes.”\no “This formula is designed to target problems that look clear and watery and\u002For may contain flakes”\n• Superior Cow Cream\no “… Sore Teats – Flaky Milk – High S.C.C”\no “…works beneath the skins surface at a deeper level than traditional udder creams.”\n• Super Cow Udder Mint\no “Super Cow Udder Mint is not for every mastitis case. In most cases, Superior Cow Cream will work, but if a case is really bad, you want the stronger Super Cow Udder Mint.”\no “… Sore Teats – Flaky Milk – High Somatic Cell Count”\nBecause your products are intended to diagnose, cure, mitigate, treat, or prevent disease and\u002For intended to affect the structure or any function of the body of animals, they are drugs within the meaning of section 201(g)(1) of the FD&C Act, [21 U.S.C. § 321 (g)(1)]. These products are new animal drugs under section 201(v) of the FD&C Act, [21 U.S.C. 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, new animal drugs must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. The new animal drugs you market are not approved or index listed by FDA, and therefore they are unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act, [21 U.S.C. § 351(a)(5)].\nThe introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the FD&C Act, [21 U.S.C. § 331(a)].\nDrugs Without Adequate Directions for Use\nYou distribute drugs that are misbranded under section 502(f)(1) of the FD&C Act, [21 U.S.C. § 352(f)(1)] because their labeling lacks adequate directions for use. Adequate directions for use include, among other things, statements of all intended uses (indications), routes of administration, and frequency of administration in language understandable by laypersons. 21 CFR 201.5.\nYour website states: “Q: What are your products used for? A: Our products are a natural support system for dairy animals udder health. Our products are not FDA approved; therefore we cannot make any claims regarding our products’ purpose. It is at the farmers discretion to determine the products use.”\nYour attempt to avoid making claims about your products’ uses put animals (and the humans who might consume the byproducts of the dairy cows treated with your products) at risk by not giving users adequate directions for safe use of your drugs. You market your products for use by the general public (laypersons)–who do not know the details of your products’ formulations and how to safely use them–unless you provide that information in the product’s labeling. Although your products are unapproved, they are drugs and must therefore bear adequate directions for use, including statements of their intended uses that are understandable by laypersons.\nFor example, with respect to your products’ labeling, (including its labels and the labeling on your website):\n- Ex-Cell Countdown 7000 does not have a clear indication statement that is understandable by laypersons (e.g., vague language such as “great when you’re unsure of the problem you are having”,” “stringiness,” and other statements that laypersons may not understand, such as “high S.C.C.”). This product is also missing clear directions on the route of administration.\n- “Natural Cow Herbal Support” does not have a clear indication statement that is understandable by laypersons (e.g., use of terminology not familiar to laypersons such as, “High Somatic Cell,” and vague language such as “Irregular milk”).\n- Ex-Cell Somaticare does not have a clear indication statement that is understandable by laypersons (e.g., vague language such as “when problems look clear and watery”) and has no directions indicating how to prepare the product for administration.\n- Superior Cow Cream does not have a clear indication statement that is understandable by laypersons (“e.g., vague statements such as “Flaky Milk” and terminology not appropriate for laypersons, such as “High S.C.C”) and its labeling contains contradictory directions for frequency of use (1 to 2 fl. oz. after milking for 2 to 5 days as needed, per the label vs. twice a day for 6-10 days, per the labeling on the product’s website at synergyanimalproducts.com).\n- Super Cow Udder Mint does not have a clear indication statement that is understandable by laypersons (e.g., use of terminology not familiar to laypersons, such as “High Somatic Cell Count,” and vague language such as “Flaky Milk”).\nDuring our review, we noted many other products you sell appear to have similar issues. You should review them all to ensure they contain adequate directions for use.\nDrug Registration and Listing Violations\nSections 510(b) and (j) of the FD&C Act [21 U.S.C. § 360(b), (j)] require that manufacturers of drugs, including animal drugs, register their manufacturing establishments with FDA and provide the agency with a list of all the drugs they manufacture. Drugs that are manufactured in unregistered establishments or that have not been listed with FDA are misbranded under section 502(o) of the FD&C Act.\nNone of the animal drugs you manufacture are listed with FDA, nor have they been manufactured in a facility that is registered with FDA. Accordingly, these animal drugs are misbranded. Introduction or delivery for introduction of a misbranded animal drug into interstate commerce is prohibited under section 301(a) of the FD&C Act.\nCurrent Good Manufacturing Practice Violations\nBased on the evidence gathered during our inspection, we have determined your firm’s operations are out of compliance with the FD&C Act’s Current Good Manufacturing Practice (CGMP) requirements (section 501(a)(2)(B) of the FD&C Act, [21 U.S.C. § 351(a)(2)(B)]), and the requirements of its implementing regulation for drug products, 21 CFR Parts 210 and 211. Our inspection found that your operations were fundamentally noncompliant with CGMP in that you had no quality unit, had no written procedures applicable to the production and distribution of animal drug products, performed no testing, and kept no records pertaining to the manufacturing of these products.\nYour failure to manufacture drugs in accordance with CGMP means there is no assurance they meet the safety requirements of the FD&C Act or have the identity and strength, and meet the quality and purity characteristics, which they are represented to possess. Moreover, as you manufacture drugs for use in food-producing animals (dairy cows), your inadequate controls increase the risk that your drugs will inadvertently enter the food supply.\nDuring the most recent FDA inspection of your facility, our investigators observed specific CGMP violations, including, but not limited to, the following:\n1) Failure to establish a quality control unit. (21 CFR 211.22).\nYour firm has no quality unit (QU) or any procedures for the responsibilities of a QU (including\u002Fbut not limited to setting specifications, performing investigations, reviewing complaints, reviewing production records, conducting annual product reviews, and approving or rejecting procedures, components, labeling, and drug products). During the inspection, you stated you did not consider your products to be animal drugs and therefore you did not establish any CGMP procedures. For the reasons discussed earlier in this letter, your products are animal drugs and are therefore subject to the CGMP requirement. A functioning quality unit with approval and rejection authority is a core element of CGMP.\n2) Failure to test your drug products for conformance to final specifications. (21 CFR 211.165(a)).\nNo release testing was conducted on any animal drug products you manufactured and distributed. Testing each batch of drug products for conformance to specifications, including the identity and strength of each active ingredient, is important to ensure your drugs have the quantity of active ingredient you believe is needed to perform as you intend.\n3) Failure to test your incoming components for identity, purity, strength, and other appropriate quality attributes. (21 CFR 211.84(d)).\nYou do not perform specific identity testing for each shipment of each lot of each component you receive and then test each component for conformity with all appropriate written specifications or otherwise establish the reliability of the supplier’s analyses.\nThe quality of the components you use has a direct effect on the quality of the drug products you manufacture, and testing incoming components for identity is an important step in preventing mislabeled components from being used in manufacturing.\nAdditionally, you do not have written procedures pertaining to incoming components or any associated records including, but not limited to: written procedures related to the receiving of containers, closures, and components; the rejection of nonconforming materials; or supplier qualifications\u002Fsupplier quality agreements. You do not maintain copies of your supplier’s test results (i.e. Certificates of Analysis) for each raw material you use. You use raw materials from multiple outside suppliers.\n4) Failure to establish written procedures for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product. (21 CFR 211.67).\nDuring the inspection, we observed visibly dirty equipment (e.g., your (b)(4) tank) that you use to manufacture your drug products.\nYou do not have any written procedures or records for the cleaning and maintenance of equipment that you use to make animal drugs. This includes, but is not limited to: written procedures for cleaning, equipment cleaning validation studies, clean\u002Fdirty hold time studies, and cleaning logs. You also do not have preventative maintenance procedures and maintenance logs.\nProperly cleaned and maintained equipment is needed to prevent microbiological contamination or cross-contamination between batches of different drugs.\n5) Failure to establish master production and control records for each drug product. (21 CFR 211.186(a)).\nYou do not have master production and control records for any of the drugs you produce. These documents are the foundation of manufacturing in compliance with CGMP because they describe and define each drug, its formulation, the containers, closures, and labeling to be used, the manufacturing process to be followed (the equipment and process), and the sampling and testing to be performed, among other things. As of the inspection, you did not have formulas for any of your products in writing or any master records of any type. These master records are a basic CGMP requirement and necessary to ensure consistency between batches of drug product.\n6) Failure to prepare batch production and control records for each batch of drug product produced. (21 CFR 211.188).\nYou do not keep any written records (i.e., batch records) to document your manufacturing process.\nBatch records are critical for a variety of reasons, such as facilitating review of the production process before batch release, performing investigations, and performing recalls. You have no records to establish what lots of what components were used, how much of each component was actually added, or what manufacturing processes were performed, and you would be unable to evaluate the need for a recall if, for example, there was a recall on a lot of one of the components you used.\nIn summary, you violate the FD&C Act’s CGMP requirement by:\n- using untested components from suppliers you did not qualify; (violation 3 above)\n- to manufacture drugs with no defined process or written formulation (i.e., no master production record); (violation 5 above)\n- using equipment which we observed to be unclean during our inspection and for which you do not have cleaning procedures; (violation 4 above)\n- without keeping any written records of what components or equipment you used (i.e., no batch records); (violation 6 above)\n- without performing any tests to verify the quality of the finished product (e.g., identity and strength of active ingredient); (violation 2 above)\n- and then released the drugs without the oversight of a quality unit, which should have rejected those drugs for the reasons above. (violation 1 above)\nWe have considered your response to the Form FDA 483. You acknowledged our concern about the absence of an adequately established quality unit and committed to the establishment of a dedicated QU by (b)(4). However, your response failed to provide adequate detail and timelines regarding implementation. We are concerned that your complete lack of a quality unit has contributed–and continues to contribute–to a total failure of oversight regarding your CGMP operations. FDA has not received any recent updates from your firm regarding your proposed corrective actions. Additionally, your responses do not consider the need to mitigate any potential risks that may be associated with your CGMP-deficient processes in relation to your distributed products. During the inspection, you acknowledged the conditions cited above generally apply to all drugs you have manufactured since 2017.\nCGMP Consultant Recommended\nBased on the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and effectiveness of corrective actions and preventive actions. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. Our review indicates that you are offering for sale unapproved new animal drugs in addition to those listed above. If FDA takes legal action, the action may address all of your unapproved drugs, not just those listed above. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\nPlease direct your response to the U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “Reference 712860” in the subject line of your email.\nSincerely,\n\u002FS\u002F\nCindy L. Burnsteel, DVM\nActing Director\nDivision of Drug Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\nCc: info@synergyanimalproducts.com","Synergy Animal Products, Inc.","synergy-animal-products-inc-712860-07162025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynergy-animal-products-inc-712860-07162025","2026-10-26T08:10:09.096269+00:00","2025-09-02","712860","Animal & Veterinary","Mark A. Hassler","2026-08-19T16:27:37.151+00:00","Via Email","2025-07-16",{"id":74,"raw":75,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":90,"closeout_date":19,"issuing_office":79,"recipient_name":91,"body_fetched_at":92,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},3332,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2021-05-26T15:00:00Z\">05\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-20T04:00:00Z\">05\u002F20\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fns-products-inc-605706-05202021\">NS Products, Inc.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wolfe Vaughn and Craig Sheralyn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>NS Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11721 State Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Marysville\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98271\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 20, 2021\u003Cbr>\n\u003Cbr>\nRE: 605706\u003C\u002Fp>\n\n\u003Cp>Dear Wolfe Vaughn and Craig Sheralyn:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.naturacure.net in March 2021 and has determined that you take orders there for the product “NaturaCure.” You are also advised that the Federal Trade Commission reviewed your website in May 2021.\u003C\u002Fp>\n\n\u003Cp>The claims on your website establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On the home page:\u003Cbr>\n• “You avoid expensive surgical procedures, injections and ineffective treatments. . . NaturaCure may replace conventional fertility treatments….”\u003C\u002Fp>\n\n\u003Cp>On the “ABOUT FERTILITY” page:\u003Cbr>\n• “NaturaCure works with your body, eliminating the root cause of your specific infertility disorder (such as: ovarian cysts, uterine fibroids, endometriosis, high FSH, PCOS etc.)….”\u003Cbr>\n\u003Cbr>\n• “You will get pregnant very fast and give birth to healthy children regardless of . . . how severe or chronic your infertility disorder.”\u003C\u002Fp>\n\n\u003Cp>On the “HOW IT WORKS” page:\u003Cbr>\n• “If you suffer from infertility, tried every prescription, patch and injection the doctors have prescribed but nothing works – and want a solution that really works – then you need to try . . . NaturaCure.”\u003Cbr>\n• “Depending on individual customers and the types of infertility treated, success rates ranged from about 50% up to 98%. Included in these statistics are cases of infertility involving: . . . Obstruction of the fallopian tubess [sic] [,] Amenorrhea[,] Absent ovulation[,] Endometriosis[,] Uterine fibroids[,] . . . None liquidification of semen [sic][,] Tubal blockage[,] . . . Previous tubal ligation”\u003Cbr>\n• “Discovery NaturaCure’s Award Winning Herbal Formulation”\u003Cbr>\no “Bee Propolis - is beneficial for autoimmune related fertility issues such as recurrent miscarriage due to immunological response (mother's body attacks and rejects the fetus), autoimmune related premature ovarian failure and antisperm antibody.”\u003Cbr>\no “Raspberry Fruit - Relieves impotence . . .”\u003C\u002Fp>\n\n\u003Cp>Your website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of NaturaCure for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003C\u002Fp>\n\n\u003Cp>On the “CUSTOMER REVIEWS” page:\u003Cbr>\n• “I had a miscarriage in June 2010 &amp; have been trying to conceive ever since . . . In April 2011 I decided to order NaturaCure. Started taking it in May &amp; I am now 7 weeks pregnant! . . . THIS REALLY WORKS!!!!”\u003C\u002Fp>\n\n\u003Cp>Your product “NaturaCure” is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003Cbr>\n\u003Cbr>\nYour product “NaturaCure” is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, “NaturaCure” fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions, you may also contact Aaron Dotson at aaron.dotson@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>In addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. \u003Cem>POM Wonderful LLC\u003C\u002Fem>, 155 F.T.C. 1, 60-61, (2013),&nbsp;\u003Cem>aff’d in relevant part\u003C\u002Fem>, 777 F.3d 478 (D.C. Cir. 2015); \u003Cem>Daniel Chapter One\u003C\u002Fem>, FTC Dkt. No. 9239, 2009 WL 5160000 at *16-19 (F.T.C. Dec. 24, 2009), \u003Cem>aff’d\u003C\u002Fem>, 405 Fed. Appx. 505 (D.C. Cir. 2010);&nbsp;\u003Cem>Removatron Int'l Corp\u003C\u002Fem>., 111 F.T.C. 206, 297-99 (1988), \u003Cem>aff’d\u003C\u002Fem>, 884 F.2d 1489, 1496 (1stCir. 1989); see also, \u003Cem>FTC v. Direct Mktg. Concepts\u003C\u002Fem>, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), \u003Cem>aff’d\u003C\u002Fem>, 624 F.3d 1 (1st Cir. 2010); \u003Cem>FTC v. Nat'l Urological Group, Inc\u003C\u002Fem>., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), \u003Cem>aff’d\u003C\u002Fem>, 356 Fed. Appx. 358 (11th Cir. 2009); \u003Cem>FTC v. Natural Solution, Inc\u003C\u002Fem>., No. CV 06- 6112-JFW, 2007-2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11-12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act.&nbsp;\u003Cem>See Daniel Chapter One\u003C\u002Fem>, WL 5160000 at *17-19.\u003C\u002Fp>\n\n\u003Cp>The FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. The FTC strongly urges you to review all claims for your products and ensure that those claims are supported by competent and reliable scientific evidence. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.govwithin fifteen (15) working days of receipt of this letter, of the specific actions you have taken to address FTC's concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Michael W. Roosevelt\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and\u003Cbr>\nApplied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nSerena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nWolfe Vaughn and Craig Sheralyn\n\nNS Products, Inc.\n\n11721 State Ave\n\nMarysville, WA 98271\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nMay 20, 2021\n\nRE: 605706\n\nDear Wolfe Vaughn and Craig Sheralyn:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.naturacure.net in March 2021 and has determined that you take orders there for the product “NaturaCure.” You are also advised that the Federal Trade Commission reviewed your website in May 2021.\n\nThe claims on your website establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\n\nOn the home page:\n\n• “You avoid expensive surgical procedures, injections and ineffective treatments. . . NaturaCure may replace conventional fertility treatments….”\n\nOn the “ABOUT FERTILITY” page:\n\n• “NaturaCure works with your body, eliminating the root cause of your specific infertility disorder (such as: ovarian cysts, uterine fibroids, endometriosis, high FSH, PCOS etc.)….”\n\n• “You will get pregnant very fast and give birth to healthy children regardless of . . . how severe or chronic your infertility disorder.”\n\nOn the “HOW IT WORKS” page:\n\n• “If you suffer from infertility, tried every prescription, patch and injection the doctors have prescribed but nothing works – and want a solution that really works – then you need to try . . . NaturaCure.”\n\n• “Depending on individual customers and the types of infertility treated, success rates ranged from about 50% up to 98%. Included in these statistics are cases of infertility involving: . . . Obstruction of the fallopian tubess [sic] [,] Amenorrhea[,] Absent ovulation[,] Endometriosis[,] Uterine fibroids[,] . . . None liquidification of semen [sic][,] Tubal blockage[,] . . . Previous tubal ligation”\n\n• “Discovery NaturaCure’s Award Winning Herbal Formulation”\n\no “Bee Propolis - is beneficial for autoimmune related fertility issues such as recurrent miscarriage due to immunological response (mother's body attacks and rejects the fetus), autoimmune related premature ovarian failure and antisperm antibody.”\n\no “Raspberry Fruit - Relieves impotence . . .”\n\nYour website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of NaturaCure for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\nOn the “CUSTOMER REVIEWS” page:\n\n• “I had a miscarriage in June 2010 & have been trying to conceive ever since . . . In April 2011 I decided to order NaturaCure. Started taking it in May & I am now 7 weeks pregnant! . . . THIS REALLY WORKS!!!!”\n\nYour product “NaturaCure” is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product “NaturaCure” is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, “NaturaCure” fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions, you may also contact Aaron Dotson at aaron.dotson@fda.hhs.gov.\n\nIn addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. POM Wonderful LLC, 155 F.T.C. 1, 60-61, (2013), aff’d in relevant part, 777 F.3d 478 (D.C. Cir. 2015); Daniel Chapter One, FTC Dkt. No. 9239, 2009 WL 5160000 at *16-19 (F.T.C. Dec. 24, 2009), aff’d, 405 Fed. Appx. 505 (D.C. Cir. 2010); Removatron Int'l Corp., 111 F.T.C. 206, 297-99 (1988), aff’d, 884 F.2d 1489, 1496 (1stCir. 1989); see also, FTC v. Direct Mktg. Concepts, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), aff’d, 624 F.3d 1 (1st Cir. 2010); FTC v. Nat'l Urological Group, Inc., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), aff’d, 356 Fed. Appx. 358 (11th Cir. 2009); FTC v. Natural Solution, Inc., No. CV 06- 6112-JFW, 2007-2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11-12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act. See Daniel Chapter One, WL 5160000 at *17-19.\n\nThe FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. The FTC strongly urges you to review all claims for your products and ensure that those claims are supported by competent and reliable scientific evidence. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.govwithin fifteen (15) working days of receipt of this letter, of the specific actions you have taken to address FTC's concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nActing Director\n\nOffice of Compliance\n\nCenter for Food Safety and\n\nApplied Nutrition\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission","NS Products, Inc.","ns-products-inc-605706-05202021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fns-products-inc-605706-05202021","2026-10-26T08:09:35.524317+00:00","2021-05-26","605706","Dietary Supplements","Wolfe Vaughn and Craig Sheralyn","2026-08-20T03:06:45.755+00:00","2021-05-20",{"id":95,"raw":96,"subject":101,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":18,"fei_number":19,"letter_url":106,"updated_at":107,"action_type":22,"case_status":23,"posted_date":108,"marcs_cms_no":109,"product_type":110,"closeout_date":19,"issuing_office":100,"recipient_name":111,"body_fetched_at":112,"delivery_method":113,"recipient_title":19,"reference_number":109,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},145,[97,98,99,100,101,13,13,13],"\u003Ctime datetime=\"2026-05-26T04:00:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-18T04:00:00Z\">05\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgsc-products-llc-729653-05182026\">GSC Products, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>729653\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wayne Perry\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GSC Products, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1441 Van Patten Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Duanesburg\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>12056-2522\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 18, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Wayne Perry:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your websites. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your websites, https:\u002F\u002Fsinusplumber.com and https:\u002F\u002Fwww.greensations.com, in March 2026. Your https:\u002F\u002Fsinusplumber.com website also directs consumers to your Amazon storefront to purchase your product. Based on our review, your SINUS PLUMBER Headache Nasal Spray product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). In addition, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 301(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 331(a).\u003C\u002Fp>\u003Cp>This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Based on a review of your websites, your SINUS PLUMBER Headache Nasal Spray is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your websites, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“\u003Cstrong>Drug Facts . . . Purpose\u003C\u002Fstrong>…Relieves pain and nausea…Relieves pain &amp; inflammation…Increases circulation . . . \u003Cstrong>Uses\u003C\u002Fstrong>: For the temporary relief of: ■ General headache and migraine symptoms.” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin]\u003C\u002Fp>\u003Cp>“Powerful &amp; Fast Headache Relief √ Tension √ Clusters √ Migraines” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and\u003Cbr>https:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\u003C\u002Fp>\u003Cp>“Sinus Plumber Headache Nasal Spray targets a variety of headaches with the pain relief power of capsaicin, feverfew, peppermint and caffeine.”…“This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” [from the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and https:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, SINUS PLUMBER Headache Nasal Spray is intended for use as an internal analgesic drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for this drug product identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription internal analgesic drug products, such as your SINUS PLUMBER Headache Nasal Spray, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use (hereinafter “M013”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, SINUS PLUMBER Headache Nasal Spray does not conform to the conditions specified in M013 for the reasons described below.\u003C\u002Fp>\u003Cp>Your SINUS PLUMBER Headache Nasal Spray is intended to be applied inside the nostrils. Under M013.1, only an OTC internal analgesic drug product in a form suitable for oral administration is generally recognized as safe and effective if it meets the conditions of M013. Thus, your internal analgesic drug product intended for administration inside the nostrils, does not conform to the conditions of M013.\u003C\u002Fp>\u003Cp>In addition, your SINUS PLUMBER Headache Nasal Spray labeling includes intended uses that are not permitted for OTC internal analgesic drug products in M013. Specifically, claims such as “This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” and “Purpose . . . Relieves . . . nausea . . . inflammation . . . increase circulation” that suggest SINUS PLUMBER Headache Nasal Spray is intended to treat sinuses, tension, clusters, and migraines, and is intended to relieve nausea, inflammation, and increase circulation go beyond the general intended uses for an OTC internal analgesic drug product and do not conform to the permitted uses set forth in M013.50(b).\u003C\u002Fp>\u003Cp>Furthermore, your SINUS PLUMBER Headache Nasal Spray is formulated with active ingredients that are not permitted for OTC internal analgesic drug products under M013.10. Specifically, feverfew, arnica montana, oleoresin capsicum, caffeine anhydrous, and peppermint oil are not permitted as single active ingredients under M013.10, nor is this combination of active ingredients permitted under M013.20. Therefore, your SINSUS PLUMBER Headache Nasal Spray product does not conform with the conditions for lawful marketing of an OTC internal analgesic drug product as set forth in M013.\u003C\u002Fp>\u003Cp>Thus, your SINUS PLUMBER Headache Nasal Spray product does not comply with the applicable conditions specified in M013 and has not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, SINUS PLUMBER Headache Nasal Spray is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “729653” in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M013 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000027, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf]\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that SINUS PLUMBER Headache Nasal Spray is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nReference #:\n\n729653\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nWayne Perry\n\nRecipient Title\n\nFounder and President\n\nGSC Products, LLC\n\n1441 Van Patten Rd\n\nDuanesburg, NY 12056-2522\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nMay 18, 2026\nWARNING LETTER\nTo Wayne Perry:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your websites. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of your websites, https:\u002F\u002Fsinusplumber.com and https:\u002F\u002Fwww.greensations.com, in March 2026. Your https:\u002F\u002Fsinusplumber.com website also directs consumers to your Amazon storefront to purchase your product. Based on our review, your SINUS PLUMBER Headache Nasal Spray product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). In addition, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 301(a) of the FD&C Act, 21 U.S.C. 331(d) and 331(a).\nThis review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nUnapproved New Drug Violations\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nBased on a review of your websites, your SINUS PLUMBER Headache Nasal Spray is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your websites, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\n“Drug Facts . . . Purpose…Relieves pain and nausea…Relieves pain & inflammation…Increases circulation . . . Uses: For the temporary relief of: ■ General headache and migraine symptoms.” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin]\n“Powerful & Fast Headache Relief √ Tension √ Clusters √ Migraines” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and\nhttps:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\n“Sinus Plumber Headache Nasal Spray targets a variety of headaches with the pain relief power of capsaicin, feverfew, peppermint and caffeine.”…“This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” [from the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and https:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\nBased on the above labeling evidence, SINUS PLUMBER Headache Nasal Spray is intended for use as an internal analgesic drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for this drug product identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription internal analgesic drug products, such as your SINUS PLUMBER Headache Nasal Spray, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use (hereinafter “M013”).1 However, SINUS PLUMBER Headache Nasal Spray does not conform to the conditions specified in M013 for the reasons described below.\nYour SINUS PLUMBER Headache Nasal Spray is intended to be applied inside the nostrils. Under M013.1, only an OTC internal analgesic drug product in a form suitable for oral administration is generally recognized as safe and effective if it meets the conditions of M013. Thus, your internal analgesic drug product intended for administration inside the nostrils, does not conform to the conditions of M013.\nIn addition, your SINUS PLUMBER Headache Nasal Spray labeling includes intended uses that are not permitted for OTC internal analgesic drug products in M013. Specifically, claims such as “This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” and “Purpose . . . Relieves . . . nausea . . . inflammation . . . increase circulation” that suggest SINUS PLUMBER Headache Nasal Spray is intended to treat sinuses, tension, clusters, and migraines, and is intended to relieve nausea, inflammation, and increase circulation go beyond the general intended uses for an OTC internal analgesic drug product and do not conform to the permitted uses set forth in M013.50(b).\nFurthermore, your SINUS PLUMBER Headache Nasal Spray is formulated with active ingredients that are not permitted for OTC internal analgesic drug products under M013.10. Specifically, feverfew, arnica montana, oleoresin capsicum, caffeine anhydrous, and peppermint oil are not permitted as single active ingredients under M013.10, nor is this combination of active ingredients permitted under M013.20. Therefore, your SINSUS PLUMBER Headache Nasal Spray product does not conform with the conditions for lawful marketing of an OTC internal analgesic drug product as set forth in M013.\nThus, your SINUS PLUMBER Headache Nasal Spray product does not comply with the applicable conditions specified in M013 and has not otherwise been found GRASE.2 Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug.\nThe introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, SINUS PLUMBER Headache Nasal Spray is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “729653” in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_______________________\n1 M013 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000027, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf]\n2 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that SINUS PLUMBER Headache Nasal Spray is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).","GSC Products, LLC","gsc-products-llc-729653-05182026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgsc-products-llc-729653-05182026","2026-10-26T08:08:50.940349+00:00","2026-05-26","729653","Drugs Over-the-Counter Drugs","Wayne Perry","2026-08-19T04:39:54.735+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2026-05-18",{"id":116,"raw":117,"subject":122,"body_html":123,"body_text":124,"firm_name":125,"letter_id":126,"created_at":63,"fei_number":19,"letter_url":127,"updated_at":128,"action_type":22,"case_status":23,"posted_date":129,"marcs_cms_no":130,"product_type":131,"closeout_date":19,"issuing_office":121,"recipient_name":19,"body_fetched_at":132,"delivery_method":133,"recipient_title":19,"reference_number":134,"action_taken_date":135,"medical_device_id":19,"response_letter_date":19},546,[118,119,120,121,122,13,13,13],"\u003Ctime datetime=\"2025-10-07T04:00:00Z\">10\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-02T04:00:00Z\">10\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flbc-products-inc-717608-10022025\">LBC Products Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501315\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>LBC Products Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6360 South Pecos Road, Suite 8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89120\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lehab@lbcproducts.com\"> lehab@lbcproducts.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 2, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that LBC PRODUCTS INC. sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States the following e-liquid products that lack a marketing authorization order: HUSTLER PREMIUM E-LIQUID STRAWBERRY BLONDE 60 ML 3MG\u002FML.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501315, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501315\n\nProduct:\n\nTobacco\n\nRecipient:\n\nLBC Products Inc.\n\n6360 South Pecos Road, Suite 8\n\nLas Vegas, NV 89120\n\nUnited States\n\nlehab@lbcproducts.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 2, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that LBC PRODUCTS INC. sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States the following e-liquid products that lack a marketing authorization order: HUSTLER PREMIUM E-LIQUID STRAWBERRY BLONDE 60 ML 3MG\u002FML.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501315, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","LBC Products Inc.","lbc-products-inc-717608-10022025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flbc-products-inc-717608-10022025","2026-10-26T08:09:12.826898+00:00","2025-10-07","717608","Tobacco","2026-08-19T16:14:50.902+00:00","VIA UPS and Electronic Mail","ER2501315","2025-10-02",{"id":137,"raw":138,"subject":122,"body_html":142,"body_text":143,"firm_name":144,"letter_id":145,"created_at":146,"fei_number":19,"letter_url":147,"updated_at":148,"action_type":22,"case_status":23,"posted_date":149,"marcs_cms_no":150,"product_type":131,"closeout_date":19,"issuing_office":121,"recipient_name":19,"body_fetched_at":151,"delivery_method":133,"recipient_title":19,"reference_number":19,"action_taken_date":152,"medical_device_id":19,"response_letter_date":19},2514,[139,140,141,121,122,13,13,13],"\u003Ctime datetime=\"2022-08-16T13:20:00Z\">08\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-12T04:00:00Z\">08\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frev-products-llc-639730-08122022\">Rev Products LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Rev Products LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1309 Coffeen Avenue, Suite 2579\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sheridan\u003C\u002Fspan>, \u003Cspan>WY\u003C\u002Fspan> \u003Cspan>82801\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@revecig.com\"> info@revecig.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 12, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed https:\u002F\u002Frevecig.com and determined your ENDS products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Frevecig.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Banana Ice, Cola Ice, and Ice Grape.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Tobacco Products Manufactured in an Unregistered Establishment Are Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review indicates that you did not register your manufacturing establishment, located at 1309 Coffeen Avenue Suite 2579 Sheridan, WY 82801, as required by section 905(c) of the FD&amp;C Act (21 U.S.C. § 387e(c)). Specifically, section 905(c) states that “[e]very person upon first engaging in the manufacture, preparation, compounding, or processing of a tobacco product or tobacco products in any establishment owned or operated in any State by that person shall immediately register with the Secretary that person's name, place of business, and such establishment.”\u003C\u002Fp>\n\n\u003Cp>Because your establishment was not registered in accordance with section 905(c) of the FD&amp;C Act, your tobacco products that were manufactured, prepared, propagated, compounded, or processed at that establishment are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)). The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&amp;C Act (21 U.S.C. § 331(a)). The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201806, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Cloud Peak Law, LLC\u003Cbr>\nAttn: Andrew Pierce\u003Cbr>\n1095 Sugar View Dr., Ste. 500\u003Cbr>\nSheridan, WY 828801\u003Cbr>\nreports@cloudpeaklaw.com\u003C\u002Fp>\n\n\u003Cp>Domains By Proxy, LLC\u003Cbr>\nabuse@domainsbyproxy.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>InMotion Hosting, Inc.\u003Cbr>\nabuse@inmotionhosting.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRev Products LLC\n\n1309 Coffeen Avenue, Suite 2579\n\nSheridan, WY 82801\n\nUnited States\n\ninfo@revecig.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nAugust 12, 2022\n\nWARNING LETTER\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed https:\u002F\u002Frevecig.com and determined your ENDS products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Frevecig.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Banana Ice, Cola Ice, and Ice Grape.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nTobacco Products Manufactured in an Unregistered Establishment Are Misbranded\n\nOur review indicates that you did not register your manufacturing establishment, located at 1309 Coffeen Avenue Suite 2579 Sheridan, WY 82801, as required by section 905(c) of the FD&C Act (21 U.S.C. § 387e(c)). Specifically, section 905(c) states that “[e]very person upon first engaging in the manufacture, preparation, compounding, or processing of a tobacco product or tobacco products in any establishment owned or operated in any State by that person shall immediately register with the Secretary that person's name, place of business, and such establishment.”\n\nBecause your establishment was not registered in accordance with section 905(c) of the FD&C Act, your tobacco products that were manufactured, prepared, propagated, compounded, or processed at that establishment are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)). The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&C Act (21 U.S.C. § 331(a)). The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201806, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nCloud Peak Law, LLC\n\nAttn: Andrew Pierce\n\n1095 Sugar View Dr., Ste. 500\n\nSheridan, WY 828801\n\nreports@cloudpeaklaw.com\n\nDomains By Proxy, LLC\n\nabuse@domainsbyproxy.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nInMotion Hosting, Inc.\n\nabuse@inmotionhosting.com","Rev Products LLC","rev-products-llc-639730-08122022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frev-products-llc-639730-08122022","2026-10-26T08:09:49.092354+00:00","2022-08-16","639730","2026-08-20T01:40:04.669+00:00","2022-08-12",{"id":154,"raw":155,"subject":122,"body_html":159,"body_text":160,"firm_name":161,"letter_id":162,"created_at":163,"fei_number":19,"letter_url":164,"updated_at":165,"action_type":22,"case_status":23,"posted_date":166,"marcs_cms_no":167,"product_type":131,"closeout_date":19,"issuing_office":121,"recipient_name":168,"body_fetched_at":169,"delivery_method":29,"recipient_title":19,"reference_number":170,"action_taken_date":166,"medical_device_id":19,"response_letter_date":19},1185,[156,157,158,121,122,13,13,13],"\u003Ctime datetime=\"2024-10-30T15:00:00Z\">10\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-30T04:00:00Z\">10\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbfl-metal-products-co-ltd-695371-10302024\">BFL Metal Products Co., LTD\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402224\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Liang Lihong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>BFL Metal Products Co., LTD\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Guangdong Sheng\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Lily@dallltd.com\"> Lily@dallltd.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@qr-joy.com\"> sales@qr-joy.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 30, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Liang Lihong:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Ffumevapors.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobaccoproducts\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacturer and offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: WeFume Vape 30K Puffs – Lychee Soda and WeFume Vape 30K Puffs – Apple Pineapple.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Considerations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA finds these products particularly concerning because the product labeling and\u002For advertising for WeFume Vape 30K Puffs (see Exhibit A) may be attractive to youth by imitating a smartphone or other smart technology (see Exhibit B).\u003C\u002Fp>\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F695371-BFL_0.png\" alt=\"695371-Watchface\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cp>In particular, youth and young adults may be attracted to the products’ design and functionalities imitating smart phones and other smart technology, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Featuring customizable settings, Bluetooth connectivity, and access to 16 different apps like calls, music, and voice assistants”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Further, the products’ design may be attractive to youth because the design helps conceal the nature of the product as a tobacco product from parents, teachers, or other adults, and therefore could be openly carried without revealing to parents, teachers, or other adults that the products are tobacco products. FDA is concerned about the youth appeal and widespread youth use of ENDS products, which are the most common tobacco products used by students reporting current tobacco use Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketingorders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402224, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>John E. Verbeten\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Fume\u003Cbr>\n1210 Stirling Rd Unit 10B\u003Cbr>\nHollywood, FL 33004\u003Cbr>\ninfo@fume.com\u003Cbr>\nsupport@fume.com\u003C\u002Fp>\n\n\u003Cp>QR Joy Inc\u003Cbr>\nAttn: Shlomi Evgi and Yogev Shvo\u003Cbr>\n8570 Stirling Rd Suite 102\u003Cbr>\nHollywood, FL 33024\u003C\u002Fp>\n\n\u003Cp>QR Joy Inc.\u003Cbr>\n1790 SW 30th Ave\u003Cbr>\nHallandale, FL 33009\u003C\u002Fp>\n\n\u003Cp>QR Joy Inc.\u003Cbr>\n425 NW 10th Terrace\u003Cbr>\nHallandale Beach, Florida 33009\u003Cbr>\ninfo@qr-joy.com\u003C\u002Fp>\n\n\u003Cp>Alibaba Cloud Computing (Beijing) Co., Ltd.\u003Cbr>\nDomainAbuse@service.aliyun.com\u003C\u002Fp>\n\n\u003Cp>Hostinger International Ltd.\u003Cbr>\nnre@hostinger.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\nRW2402224\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nLiang Lihong\n\nBFL Metal Products Co., LTD\n\nGuangdong Sheng,\n\nChina\n\nLily@dallltd.com\n\nsales@qr-joy.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 30, 2024\n\nWARNING LETTER\n\nDear Liang Lihong:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Ffumevapors.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobaccoproducts\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacturer and offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: WeFume Vape 30K Puffs – Lychee Soda and WeFume Vape 30K Puffs – Apple Pineapple.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nAdditional Considerations\n\nFDA finds these products particularly concerning because the product labeling and\u002For advertising for WeFume Vape 30K Puffs (see Exhibit A) may be attractive to youth by imitating a smartphone or other smart technology (see Exhibit B).\n\nIn particular, youth and young adults may be attracted to the products’ design and functionalities imitating smart phones and other smart technology, including:\n\n“Featuring customizable settings, Bluetooth connectivity, and access to 16 different apps like calls, music, and voice assistants”\n\nFurther, the products’ design may be attractive to youth because the design helps conceal the nature of the product as a tobacco product from parents, teachers, or other adults, and therefore could be openly carried without revealing to parents, teachers, or other adults that the products are tobacco products. FDA is concerned about the youth appeal and widespread youth use of ENDS products, which are the most common tobacco products used by students reporting current tobacco use Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketingorders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402224, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJohn E. Verbeten\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nFume\n\n1210 Stirling Rd Unit 10B\n\nHollywood, FL 33004\n\ninfo@fume.com\n\nsupport@fume.com\n\nQR Joy Inc\n\nAttn: Shlomi Evgi and Yogev Shvo\n\n8570 Stirling Rd Suite 102\n\nHollywood, FL 33024\n\nQR Joy Inc.\n\n1790 SW 30th Ave\n\nHallandale, FL 33009\n\nQR Joy Inc.\n\n425 NW 10th Terrace\n\nHallandale Beach, Florida 33009\n\ninfo@qr-joy.com\n\nAlibaba Cloud Computing (Beijing) Co., Ltd.\n\nDomainAbuse@service.aliyun.com\n\nHostinger International Ltd.\n\nnre@hostinger.com","BFL Metal Products Co., LTD","bfl-metal-products-co-ltd-695371-10302024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbfl-metal-products-co-ltd-695371-10302024","2026-10-26T08:08:03.9974+00:00","2024-10-30","695371","Liang Lihong","2026-08-19T20:15:46.236+00:00","RW2402224",{"id":172,"raw":173,"subject":38,"body_html":177,"body_text":178,"firm_name":179,"letter_id":180,"created_at":63,"fei_number":19,"letter_url":181,"updated_at":182,"action_type":22,"case_status":23,"posted_date":183,"marcs_cms_no":184,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":185,"body_fetched_at":186,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":187,"medical_device_id":19,"response_letter_date":19},746,[174,175,176,37,38,13,13,13],"\u003Ctime datetime=\"2025-07-29T04:00:00Z\">07\u002F29\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-21T04:00:00Z\">07\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonkos-surgical-inc-712573-07212025\">Onkos Surgical, Inc. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Patrick J. Treacy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Onkos Surgical, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>77 E Halsey Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Parsippany\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ptreacy@onkossurgical.com\"> ptreacy@onkossurgical.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 712573\u003C\u002Fp>\u003Cp>July 21, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Patrick J. Treacy:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Parsippany, NJ from February 4, 2025 through April 4, 2025, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer of the ELEOS Limb Salvage System indicated for use in total hip and knee arthroplasty for reduction or relief of pain and\u002For improved hip function in skeletally mature patients with select conditions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Len Tokish, Vice President of Quality Assurance and Regulatory Affairs dated May 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to adequately implement the “Approved Supplier List” section of your “Supplier, Purchasing and Inspection Controls” procedure (SOP-013; Rev. 0-6; Effective: 4\u002F25\u002F16 - 2\u002F3\u002F25) which requires that you “\u003Cem>ensure compliance to ISO 13485\u003C\u002Fem>” for your Tier 1 suppliers as a “method of control” over approved suppliers. For example, you did not ensure compliance to the process validation requirements (clause 7.5.6) of ISO 13485 (Medical Devices – Quality Management Systems – Requirements for regulatory purposes) for the following three (3) Tier 1 suppliers in that you failed to adequately assess and\u002For document an assessment of the acceptability of their cleaning validations meant to demonstrate that in-process or final cleaning of your ELEOS Implant Devices and Instruments consistently meet your specifications for cleanliness:\u003C\u002Fp>\u003Cp>a. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – Tier \u003Cstrong>(b)(4)\u003C\u002Fstrong> Final Cleaner of ELEOS Implant Devices\u003C\u002Fp>\u003Cp>i. You approved the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validation test report TR-2771D-01 (Rev. 1-2; Approved: 1\u002F24\u002F19 and 9\u002F10\u002F21) from this supplier despite it failing to define the maximum allowable devices per gallon per run, as required by section 9.2 of the corresponding test protocol TP-2771D-01 (Rev. 2; Approved: 9\u002F10\u002F21) which states “***\u003Cem>The main cleaning parameters that can impact the efficacy of the cleaning process include ***Quantity of parts\u003C\u002Fem> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)***.”\u003C\u002Fp>\u003Cp>Similarly, you approved \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validation test report TR-2771E-01 (Rev. 1; Approved: 3\u002F18\u002F19) from this supplier despite it failing to document the maximum allowable quantity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> per run, as required by sections 9.3, 9.4, and 9.5 of the corresponding test protocol TP-2771E-01 (Rev. 1; Approved: 8\u002F28\u002F18) which state “***\u003Cem>To validate the cleaning process, parts shall be cleaned using\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>over\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>runs***To create a\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>batch of product***Clean what is expected to be a\u003C\u002Fem> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” load in \u003Cstrong>(b)(4)\u003C\u002Fstrong>***\u003Cem>A cleaning process should not alter the appearance of parts or cause damage. If applicable, appropriate fixtures to hold the components during cleaning should be included in the study and used in routine production\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>ii. You failed to adequately assess differences in product design and geometrical configurations of candidate devices for the adoption into device families of existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validations conducted by this supplier because you did not accurately answer guiding questions contained in your “\u003Cem>Assessment of Product Change or New Product Adoption for Cleaning Processes\u003C\u002Fem>” reports. For example:\u003C\u002Fp>\u003Cp> The AC-2772-01 (Rev. 01; Effective: 7\u002F25\u002F19) and AC-277D-01 (Rev. 2; Effective: 2\u002F26\u002F21) reports show that you failed to document rationale to support your answers of “no” to the question posed in section 2 – “\u003Cem>In relation to the existing product, does the candidate product have a similar or less complex design?\u003C\u002Fem>” – despite the candidate devices having 4 grooves, a drive, or a male thread compared to the worst-case and comparison devices, which have none of these features.\u003C\u002Fp>\u003Cp> The AC-2772-02 report (Rev. 1; Effective: 3\u002F23\u002F20) shows that you incorrectly answered “no” to the question posed in section 2 – “\u003Cem>In relation to the existing product, does the candidate product have fewer\u002Fsmaller or equivalent cannulated portions or lumens?\u003C\u002Fem>” – when you compared the candidate device (segmental proximal femur, PF-2000L-02M), which has 7 cannulated holes, to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> device (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and comparison devices (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), which contain no holes.\u003C\u002Fp>\u003Cp>b. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – Tier 1 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Implant Devices\u003C\u002Fp>\u003Cp>Although requested during the inspection, your Vice President of Quality Affairs and Regulatory Affairs was unable to provide documentation that you assessed the adequacy of the cleaning validations conducted in 2009 by this supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In reviewing the “Process Validation of***\u003Cstrong>(b)(4)\u003C\u002Fstrong> Clean Line” Operational Qualification (OQ) (E118-2116; Rev. 1; Approved: 1\u002F9\u002F09) and Performance Qualification (PQ) (E118-2116; Rev. 1; Approved: 2\u002F3\u002F09), the following deficiencies were observed:\u003C\u002Fp>\u003Cp>i. The rationale in the PQ report to accept deviations from the nominal operating range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F) because OQ data showed that the process monitoring, total organic carbon (TOC), and gravimetric produced acceptable results at worst-case conditions for temperatures as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F and control charts indicated a lower control limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (Deviation 3) does not take into account the vast differences in sample sizes (\u003Cstrong>(b)(4)\u003C\u002Fstrong> vs. \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and acceptance criterion (Ppk \u003Cstrong>(b)(4)\u003C\u002Fstrong> vs. Ppk \u003Cstrong>(b)(4)\u003C\u002Fstrong>) between PQ and OQ for the same tests (TOC and gravimetric analysis) such that passing results for parameters established during OQ are not transferrable to PQ.\u003C\u002Fp>\u003Cp>ii. This supplier failed to document rationale in the OQ and PQ reports for why it was acceptable to convert all negative values measured for the corrected “\u003Cem>mass recovered from gravimetric\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> and corrected “\u003Cem>mass recovered from\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> to 0.00 mg in the “\u003Cem>Gravimetric Extraction Summary\u003C\u002Fem>” table during gravimetric testing, thereby passing the acceptance criteria of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002Fcm\u003Csup>2\u003C\u002Fsup> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). For example, during OQ, an \u003Cstrong>(b)(4)\u003C\u002Fstrong> value as high as -1.59 mg for “Hip – 4” was converted to 0.00 mg without an explanation that accounts for the possibility of testing errors, inadequate test methodology (e.g., lack of sensitivity of testing methods), and uncalibrated state of measuring equipment.\u003C\u002Fp>\u003Cp>c. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Implant Devices &amp; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Instruments\u003C\u002Fp>\u003Cp>You approved the adoption of new products into this supplier’s existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validations titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Equipment &amp; Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) and “Zenith Final Ultrasonic Cleaning Equipment &amp; Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) per your Cleaning, Assembly, Packaging and Sterility (CAPS) Checklists for Project # 16-001 (Approved 10\u002F2\u002F24) and Project # 16-003 (Approved 4\u002F19\u002F24) referencing memo “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning” (2\u002F14\u002F19) and results of a 3rd party audit conducted 2\u002F23\u002F18 despite the following deficiencies:\u003C\u002Fp>\u003Cp>i. The OQ and PQ protocols failed to require documentation of the load configurations for all work orders in that the Vice President of Quality Affairs and Regulatory Affairs was not able to determine if devices were put in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> or broken up into \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>ii. The PQ protocol failed to include documentation of valid statistical rationale for cytotoxicity, endotoxin, and\u002For particulate testing. For example, the quantity tested per work order (66672, 66921, 66922) for cytotoxicity and endotoxin was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> respectively and the quantity tested per work order (66675, 66919, 66920) for cytotoxicity, endotoxin, and particulate was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The immediate correction is to impose heightened controls at each supplier commensurate with risk until new worst-case cleaning validations can be completed that addresses each of the observed deficiencies for \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 1\u002F15\u002F26, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (target date not provided), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 3\u002F1\u002F26 at the latest.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an assessment of worst-case part justification by family was completed to establish new limits placed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You plan to add this new loading criteria to the final DHR review by 7\u002F15\u002F25. In addition, you plan to require an update to \u003Cstrong>(b)(4)\u003C\u002Fstrong> internal procedure to include predicate cleaning validation review by 7\u002F15\u002F25. Based on the results of the new cleaning validation, you plan to revise top level procedures by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an assessment of worst-case part justification was conducted and monitoring was put in place to control product release by assessing endotoxicity and cytotoxicity on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. In addition, you plan to require an update to this supplier’s internal procedures to improve notification of triggers to their customers by 7\u002F1\u002F25.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to conduct an assessment for worst-case part challenge per part family by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For all instruments, interim clean line controls were implemented to require shipment of instruments to your firm and analyses of those instruments, which includes worst-case part and part family assessments prior to adoption into your clean-line part family. All parts successfully assessed will then be cleaned using your validated clean line prior to release for commercial distribution. All implants will continue to be shipped to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning and will fall under controls established for therein.\u003C\u002Fp>\u003Cp>Corrective actions include updating your supplier control and design control procedures to establish minimum requirements for cleaning validations of implants and instruments, including defining key product attributes to consider when forming product families and what considerations trigger a new worst-case within a product family or new product cleaning family; creation of a procedure for part families and worst-case parts per family which defines and evaluates implant and instrument cleaning families to facilitate consistent assessment of device cleaning families across products; determination and justification of minimum sample size and attributes (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) for validations; development of a cleaning validation checklist and modification of a supplier audit checklist that captures the aforementioned worst-case part determination, sample sizes, and minimum attributes that will be used during supplier assessment as part of design transfer and new supplier onboarding, manufacturing transfer, and supplier audit; and periodic review of validations on a scheduled interval against new standards and requirements by 6\u002F15\u002F25.\u003C\u002Fp>\u003Cp>However, no target date was provided for the new cleaning validation planned for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, please provide a response regarding how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement your Post Market Surveillance procedure (QP-18-004; Rev. 3; Effective: 6\u002F30\u002F22) which requires opening a CAPA when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis of infection complaints “***\u003Cem>is more than\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>above the literature rate or\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>are above the literature rate\u003C\u002Fem>***” for a given procedure type. For example, you did not initiate CAPAs when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis for infection complaints exceeded the rates of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for the distal femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong>); \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for proximal femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>); and \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for total femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) established in the journal article by Henderson et. al “\u003Cem>Failure Mode Classification for Tumor Endoprostheses: Retrospective Review of Five Institutions and a Literature Review\u003C\u002Fem>” (Journal Bone and Joint Surgery 2011) by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. Under CAPA 24-011 which was initiated on 9\u002F11\u002F24 to create a more robust methodology for trending and analyzing infection related complaints, you conducted a revised retrospective assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> infection rates from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> (TM-25-0002; Rev. B; Approved 5\u002F14\u002F25) based on additional literature data to support updated baseline infection rates by procedure type. As a part of the corrective action, you plan to create new work instructions with requirements to perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> trend reporting for infections and \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> trend reports for all other postmarket surveillance key performance indicators (KPIs); revise management review presentation slides and quality planning, postmarket surveillance, complaint handling, and CAPA procedures; and provide training on the new procedures. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to adequately establish and maintain procedures for validating the device design with regards to risk analysis, as required by 21 CFR 820.30(g).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 5.9 of your “Risk Management Process” procedure (SOP-008; Rev. 4-5; Effective: 3\u002F22\u002F23 - 1\u002F17\u002F25) which requires postmarket re-evaluation of risk management for a medical device as well as monitoring of postmarket information “***\u003Cem>for assurance that no unacceptable or previously unrecognized failure modes occur. In the event of such an occurrence the potential that the residual risk or its acceptability has changed and the impact on the previously implemented risk control measures shall be evaluated\u003C\u002Fem>***.” For example, you failed to utilize the real rate of occurrence for loosening in complaints PCR 11272023-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), PCR 05132024-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), and PCR 10172024-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) calculated at 3.27%, 0.149%, and 3.1%, respectively, to evaluate the need to update the occurrence rating in the corresponding ELEOS Stem Implant Risk Table (Project # 16-001\u002F16-003; Rev. E; Approved: 4\u002F1\u002F19), which remains unchanged at \u003Cstrong>(b)(4)\u003C\u002Fstrong>% through \u003Cstrong>(b)(4)\u003C\u002Fstrong>% since April 1, 2019.\u003C\u002Fp>\u003Cp>An update to the postmarket rate of occurrence changes the failure mode from an acceptable risk to a conditionally acceptable risk, thereby requiring an evaluation for the need for additional risk controls and assessment for the acceptability of the residual risk as required under sections 5.6 and 5.7 of SOP-008.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. The immediate correction is to evaluate literature, sources, historical data, and\u002For engineering estimates against postmarket data and update the occurrence rates for the hazardous situations associated with the ELEOS Limb Salvage system by \u003Cstrong>(b)(4)\u003C\u002Fstrong> followed by a revision of the corresponding risk tables by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As a part of the corrective action, you plan to revise SOP-008 to ensure that the methods used to create and maintain risk assessment tables are well-defined and create work instructions for conducting risk assessments utilizing postmarket information by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to establish and maintain procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics, as required by 21 CFR 820.250(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 1.1 of your “Sample Size and Statistical Techniques” procedure (SOP-014; Rev. 2-4; Effective: 8\u002F16\u002F18 - 3\u002F22\u002F23) which “***\u003Cem>identifies valid statistical techniques that are used to establish, control and verify the acceptability of process capability and product characteristics***” pertaining to “***inspections and other analyses of objective data\u003C\u002Fem>***” of ELEOS Implant Devices received from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. during incoming inspections. For example, your Vice President of Quality Affairs and Regulatory Affairs acknowledged that the sampling plans of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampled incoming device history records (DHRs) from this supplier were not traceable to a documented valid statistical rationale.\u003C\u002Fp>\u003Cp>a. You reviewed and approved incoming DHRs for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 11\u002F2\u002F20 and 11\u002F29\u002F21 where a sampling plan of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was used to inspect critical features during in-process inspections for which there is no documented rationale for use of this sampling plan. For example, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Tibial Baseplate Component, Size 4 (Part # TB-2204E-01M) Implant Devices, the line profile (curve) for \u003Cstrong>(b)(4)\u003C\u002Fstrong> each were inspected against a specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Similarly, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Collar, 28 Diameter, Round, Porous, HA Treated (Part # HB-2800R-03M) Implant Devices, the diameter for \u003Cstrong>(b)(4)\u003C\u002Fstrong> each was inspected against a specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>b. You reviewed and approved incoming DHRs (Lot #: \u003Cstrong>(b)(4)\u003C\u002Fstrong>) where sampling plans utilized an AQL (acceptable quality limit) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> to inspect features during in-process and final inspections for which there are no documented rationales for use of these sampling plans. For example, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Segmental Proximal Femur, Plasma Spray, Left 98 MM (Part # PF-2000L-02M) Implant Devices, the dimensional specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was inspected at an AQL level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> during final inspection on 1\u002F23\u002F24.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The immediate corrections are to use a checklist to reassess and document rationales for acceptability of the existing AQLs selected for all contract manufactured ELEOS part families from 1\u002F1\u002F21 to 4\u002F1\u002F25 and share the rationales with the contract manufacturers by 11\u002F21\u002F25 and update SCAR 25-01 to require the contract manufacturer to include documented evidence for all inspected dimensions and associated AQL quantities by 5\u002F14\u002F25. As a part of the corrective actions, you plan to update SOP-014 and WI-013-31 (Incoming Inspection Process) to require review of incoming inspection results, consolidation of sampling procedures, set up traceable valid statistical rationales, and confirm AQLs by 7\u002F6\u002F25; update SOP-007 (Design Control) and various design transfer, manufacturing transfer, supplier, and incoming inspection checklists to include instructions for the acceptance of a supplier’s sampling procedure with confirmation of conformance to those procedures during incoming inspection of supplier DHRs by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and develop \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection requirement checklists for all suppliers with a sampling procedure traceable to a valid statistical rationale based on \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 7\u002F18\u002F25. However, these corrections and\u002For corrective actions only address the need to have a statistically valid rationale for the use of sampling plans which follow AQL and not sampling plans which utilize inspections of select critical features for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices. Therefore, please provide a response on how you plan to address the above deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s ELEOS Limb Salvage System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to submit a medical device Report of Correction or Removal for an action initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR Part 806.10. For example:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>a. Your firm conducted a removal of numerous part numbers and lot numbers of your ELEOS Limb Salvage System due to sterile packaging separation and damaged trays, which can result in extended surgery time or potential patient infection. Your firm sent a Customer Notification for this issue on 6\u002F28\u002F2023. This action meets the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>b. On or about 10\u002F15\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Male-Female Midsection 40MM, due to taper post misalignment, which can result in extended surgery time or improperly assembled devices leading to future disassociation. Your firm sent a Customer Notification for this issue dated 9\u002F20\u002F2024. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>c. On or about 1\u002F22\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Collar Stem, Cemented, Fluted 13MM X 120MM and Collar Stem, Cemented, Fluted 15MM X 120MM due to mislabeling of the devices, which can result in implantation or attempted implantation of an incorrect stem size, potentially extending surgery time or causing the patient to need revision surgery. Your firm sent a Customer Notification for this issue on 12\u002F22\u002F2023. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response, dated 5\u002F14\u002F2025, regarding Observation 5 cannot be determined because we do not have assurance that your firm will make appropriate decisions following 21 CFR 806 in the future, based on your firm’s root cause stating that your firm’s SOP is ambiguous and subjective. Your firm adequately reported by retroactively submitting Reports of Correction or Removal to FDA addressing each of the three issues on 4\u002F25\u002F2025.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 712573” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Len Tokish\u003Cbr>VP of Quality Assurance &amp; Regulatory Affairs\u003Cbr>ltokish@onkossurgical.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPatrick J. Treacy\n\nRecipient Title\n\nPresident and CEO\n\nOnkos Surgical, Inc.\n\n77 E Halsey Rd\n\nParsippany, NJ 07054\n\nUnited States\n\nptreacy@onkossurgical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 712573\nJuly 21, 2025\nDear Mr. Patrick J. Treacy:\nDuring an inspection of your firm located in Parsippany, NJ from February 4, 2025 through April 4, 2025, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer of the ELEOS Limb Salvage System indicated for use in total hip and knee arthroplasty for reduction or relief of pain and\u002For improved hip function in skeletally mature patients with select conditions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Len Tokish, Vice President of Quality Assurance and Regulatory Affairs dated May 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50.\nSpecifically, you failed to adequately implement the “Approved Supplier List” section of your “Supplier, Purchasing and Inspection Controls” procedure (SOP-013; Rev. 0-6; Effective: 4\u002F25\u002F16 - 2\u002F3\u002F25) which requires that you “ensure compliance to ISO 13485” for your Tier 1 suppliers as a “method of control” over approved suppliers. For example, you did not ensure compliance to the process validation requirements (clause 7.5.6) of ISO 13485 (Medical Devices – Quality Management Systems – Requirements for regulatory purposes) for the following three (3) Tier 1 suppliers in that you failed to adequately assess and\u002For document an assessment of the acceptability of their cleaning validations meant to demonstrate that in-process or final cleaning of your ELEOS Implant Devices and Instruments consistently meet your specifications for cleanliness:\na. (b)(4) – Tier (b)(4) Final Cleaner of ELEOS Implant Devices\ni. You approved the (b)(4) cleaning validation test report TR-2771D-01 (Rev. 1-2; Approved: 1\u002F24\u002F19 and 9\u002F10\u002F21) from this supplier despite it failing to define the maximum allowable devices per gallon per run, as required by section 9.2 of the corresponding test protocol TP-2771D-01 (Rev. 2; Approved: 9\u002F10\u002F21) which states “***The main cleaning parameters that can impact the efficacy of the cleaning process include ***Quantity of parts ((b)(4))***.”\nSimilarly, you approved (b)(4) cleaning validation test report TR-2771E-01 (Rev. 1; Approved: 3\u002F18\u002F19) from this supplier despite it failing to document the maximum allowable quantity of (b)(4) and (b)(4) per run, as required by sections 9.3, 9.4, and 9.5 of the corresponding test protocol TP-2771E-01 (Rev. 1; Approved: 8\u002F28\u002F18) which state “***To validate the cleaning process, parts shall be cleaned using (b)(4) over (b)(4) runs***To create a (b)(4) batch of product***Clean what is expected to be a “(b)(4)” load in (b)(4)***A cleaning process should not alter the appearance of parts or cause damage. If applicable, appropriate fixtures to hold the components during cleaning should be included in the study and used in routine production***.”\nii. You failed to adequately assess differences in product design and geometrical configurations of candidate devices for the adoption into device families of existing (b)(4) cleaning validations conducted by this supplier because you did not accurately answer guiding questions contained in your “Assessment of Product Change or New Product Adoption for Cleaning Processes” reports. For example:\n The AC-2772-01 (Rev. 01; Effective: 7\u002F25\u002F19) and AC-277D-01 (Rev. 2; Effective: 2\u002F26\u002F21) reports show that you failed to document rationale to support your answers of “no” to the question posed in section 2 – “In relation to the existing product, does the candidate product have a similar or less complex design?” – despite the candidate devices having 4 grooves, a drive, or a male thread compared to the worst-case and comparison devices, which have none of these features.\n The AC-2772-02 report (Rev. 1; Effective: 3\u002F23\u002F20) shows that you incorrectly answered “no” to the question posed in section 2 – “In relation to the existing product, does the candidate product have fewer\u002Fsmaller or equivalent cannulated portions or lumens?” – when you compared the candidate device (segmental proximal femur, PF-2000L-02M), which has 7 cannulated holes, to the (b)(4) device ((b)(4)) and comparison devices ((b)(4)), which contain no holes.\nb. (b)(4) – Tier 1 (b)(4) Cleaner of ELEOS Implant Devices\nAlthough requested during the inspection, your Vice President of Quality Affairs and Regulatory Affairs was unable to provide documentation that you assessed the adequacy of the cleaning validations conducted in 2009 by this supplier, (b)(4). In reviewing the “Process Validation of***(b)(4) Clean Line” Operational Qualification (OQ) (E118-2116; Rev. 1; Approved: 1\u002F9\u002F09) and Performance Qualification (PQ) (E118-2116; Rev. 1; Approved: 2\u002F3\u002F09), the following deficiencies were observed:\ni. The rationale in the PQ report to accept deviations from the nominal operating range of (b)(4)°F ((b)(4), and (b)(4)°F) because OQ data showed that the process monitoring, total organic carbon (TOC), and gravimetric produced acceptable results at worst-case conditions for temperatures as low as (b)(4)°F and control charts indicated a lower control limit of (b)(4)°F (Deviation 3) does not take into account the vast differences in sample sizes ((b)(4) vs. (b)(4)) and acceptance criterion (Ppk (b)(4) vs. Ppk (b)(4)) between PQ and OQ for the same tests (TOC and gravimetric analysis) such that passing results for parameters established during OQ are not transferrable to PQ.\nii. This supplier failed to document rationale in the OQ and PQ reports for why it was acceptable to convert all negative values measured for the corrected “mass recovered from gravimetric (b)(4) and corrected “mass recovered from (b)(4) to 0.00 mg in the “Gravimetric Extraction Summary” table during gravimetric testing, thereby passing the acceptance criteria of (b)(4) mg\u002Fcm2 ((b)(4)). For example, during OQ, an (b)(4) value as high as -1.59 mg for “Hip – 4” was converted to 0.00 mg without an explanation that accounts for the possibility of testing errors, inadequate test methodology (e.g., lack of sensitivity of testing methods), and uncalibrated state of measuring equipment.\nc. (b)(4) – (b)(4) Cleaner of ELEOS Implant Devices & (b)(4) Cleaner of ELEOS Instruments\nYou approved the adoption of new products into this supplier’s existing (b)(4) cleaning validations titled “(b)(4) Cleaning Equipment & Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) and “Zenith Final Ultrasonic Cleaning Equipment & Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) per your Cleaning, Assembly, Packaging and Sterility (CAPS) Checklists for Project # 16-001 (Approved 10\u002F2\u002F24) and Project # 16-003 (Approved 4\u002F19\u002F24) referencing memo “(b)(4) Cleaning” (2\u002F14\u002F19) and results of a 3rd party audit conducted 2\u002F23\u002F18 despite the following deficiencies:\ni. The OQ and PQ protocols failed to require documentation of the load configurations for all work orders in that the Vice President of Quality Affairs and Regulatory Affairs was not able to determine if devices were put in a (b)(4) or broken up into (b)(4).\nii. The PQ protocol failed to include documentation of valid statistical rationale for cytotoxicity, endotoxin, and\u002For particulate testing. For example, the quantity tested per work order (66672, 66921, 66922) for cytotoxicity and endotoxin was (b)(4) and (b)(4) respectively and the quantity tested per work order (66675, 66919, 66920) for cytotoxicity, endotoxin, and particulate was (b)(4) and (b)(4), respectively.\nWe reviewed your firm’s response and concluded that it is not adequate. The immediate correction is to impose heightened controls at each supplier commensurate with risk until new worst-case cleaning validations can be completed that addresses each of the observed deficiencies for (b)(4) by 1\u002F15\u002F26, (b)(4) (target date not provided), and (b)(4) by 3\u002F1\u002F26 at the latest.\nFor (b)(4), an assessment of worst-case part justification by family was completed to establish new limits placed on (b)(4), and (b)(4). You plan to add this new loading criteria to the final DHR review by 7\u002F15\u002F25. In addition, you plan to require an update to (b)(4) internal procedure to include predicate cleaning validation review by 7\u002F15\u002F25. Based on the results of the new cleaning validation, you plan to revise top level procedures by (b)(4).\nFor (b)(4), an assessment of worst-case part justification was conducted and monitoring was put in place to control product release by assessing endotoxicity and cytotoxicity on a (b)(4) basis. In addition, you plan to require an update to this supplier’s internal procedures to improve notification of triggers to their customers by 7\u002F1\u002F25.\nFor (b)(4), you plan to conduct an assessment for worst-case part challenge per part family by (b)(4). For all instruments, interim clean line controls were implemented to require shipment of instruments to your firm and analyses of those instruments, which includes worst-case part and part family assessments prior to adoption into your clean-line part family. All parts successfully assessed will then be cleaned using your validated clean line prior to release for commercial distribution. All implants will continue to be shipped to (b)(4) for (b)(4) cleaning and will fall under controls established for therein.\nCorrective actions include updating your supplier control and design control procedures to establish minimum requirements for cleaning validations of implants and instruments, including defining key product attributes to consider when forming product families and what considerations trigger a new worst-case within a product family or new product cleaning family; creation of a procedure for part families and worst-case parts per family which defines and evaluates implant and instrument cleaning families to facilitate consistent assessment of device cleaning families across products; determination and justification of minimum sample size and attributes ((b)(4)) for validations; development of a cleaning validation checklist and modification of a supplier audit checklist that captures the aforementioned worst-case part determination, sample sizes, and minimum attributes that will be used during supplier assessment as part of design transfer and new supplier onboarding, manufacturing transfer, and supplier audit; and periodic review of validations on a scheduled interval against new standards and requirements by 6\u002F15\u002F25.\nHowever, no target date was provided for the new cleaning validation planned for (b)(4). Therefore, please provide a response regarding how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, you failed to implement your Post Market Surveillance procedure (QP-18-004; Rev. 3; Effective: 6\u002F30\u002F22) which requires opening a CAPA when the (b)(4) analysis of infection complaints “***is more than (b)(4) above the literature rate or (b)(4) are above the literature rate***” for a given procedure type. For example, you did not initiate CAPAs when the (b)(4) analysis for infection complaints exceeded the rates of (b)(4)% for the distal femur ((b)(4)); (b)(4)% for proximal femur ((b)(4) and (b)(4)); and (b)(4)% for total femur ((b)(4) and (b)(4)) established in the journal article by Henderson et. al “Failure Mode Classification for Tumor Endoprostheses: Retrospective Review of Five Institutions and a Literature Review” (Journal Bone and Joint Surgery 2011) by (b)(4).\nThe adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. Under CAPA 24-011 which was initiated on 9\u002F11\u002F24 to create a more robust methodology for trending and analyzing infection related complaints, you conducted a revised retrospective assessment of (b)(4) infection rates from (b)(4) to (b)(4) (TM-25-0002; Rev. B; Approved 5\u002F14\u002F25) based on additional literature data to support updated baseline infection rates by procedure type. As a part of the corrective action, you plan to create new work instructions with requirements to perform (b)(4) trend reporting for infections and (b)(4) or (b)(4) trend reports for all other postmarket surveillance key performance indicators (KPIs); revise management review presentation slides and quality planning, postmarket surveillance, complaint handling, and CAPA procedures; and provide training on the new procedures. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n3. Failure to adequately establish and maintain procedures for validating the device design with regards to risk analysis, as required by 21 CFR 820.30(g).\nSpecifically, you failed to implement section 5.9 of your “Risk Management Process” procedure (SOP-008; Rev. 4-5; Effective: 3\u002F22\u002F23 - 1\u002F17\u002F25) which requires postmarket re-evaluation of risk management for a medical device as well as monitoring of postmarket information “***for assurance that no unacceptable or previously unrecognized failure modes occur. In the event of such an occurrence the potential that the residual risk or its acceptability has changed and the impact on the previously implemented risk control measures shall be evaluated***.” For example, you failed to utilize the real rate of occurrence for loosening in complaints PCR 11272023-1 ((b)(4)), PCR 05132024-1 ((b)(4)), and PCR 10172024-1 ((b)(4)) calculated at 3.27%, 0.149%, and 3.1%, respectively, to evaluate the need to update the occurrence rating in the corresponding ELEOS Stem Implant Risk Table (Project # 16-001\u002F16-003; Rev. E; Approved: 4\u002F1\u002F19), which remains unchanged at (b)(4)% through (b)(4)% since April 1, 2019.\nAn update to the postmarket rate of occurrence changes the failure mode from an acceptable risk to a conditionally acceptable risk, thereby requiring an evaluation for the need for additional risk controls and assessment for the acceptability of the residual risk as required under sections 5.6 and 5.7 of SOP-008.\nThe adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. The immediate correction is to evaluate literature, sources, historical data, and\u002For engineering estimates against postmarket data and update the occurrence rates for the hazardous situations associated with the ELEOS Limb Salvage system by (b)(4) followed by a revision of the corresponding risk tables by (b)(4). As a part of the corrective action, you plan to revise SOP-008 to ensure that the methods used to create and maintain risk assessment tables are well-defined and create work instructions for conducting risk assessments utilizing postmarket information by (b)(4). Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n4. Failure to establish and maintain procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics, as required by 21 CFR 820.250(a).\nSpecifically, you failed to implement section 1.1 of your “Sample Size and Statistical Techniques” procedure (SOP-014; Rev. 2-4; Effective: 8\u002F16\u002F18 - 3\u002F22\u002F23) which “***identifies valid statistical techniques that are used to establish, control and verify the acceptability of process capability and product characteristics***” pertaining to “***inspections and other analyses of objective data***” of ELEOS Implant Devices received from (b)(4). during incoming inspections. For example, your Vice President of Quality Affairs and Regulatory Affairs acknowledged that the sampling plans of the (b)(4) sampled incoming device history records (DHRs) from this supplier were not traceable to a documented valid statistical rationale.\na. You reviewed and approved incoming DHRs for Lot # (b)(4) and Lot # (b)(4) on 11\u002F2\u002F20 and 11\u002F29\u002F21 where a sampling plan of (b)(4) was used to inspect critical features during in-process inspections for which there is no documented rationale for use of this sampling plan. For example, out of (b)(4) ELEOS Tibial Baseplate Component, Size 4 (Part # TB-2204E-01M) Implant Devices, the line profile (curve) for (b)(4) each were inspected against a specification of (b)(4) at (b)(4) for Lot # (b)(4). Similarly, out of (b)(4) ELEOS Collar, 28 Diameter, Round, Porous, HA Treated (Part # HB-2800R-03M) Implant Devices, the diameter for (b)(4) each was inspected against a specification of (b)(4) at (b)(4) for Lot # (b)(4).\nb. You reviewed and approved incoming DHRs (Lot #: (b)(4)) where sampling plans utilized an AQL (acceptable quality limit) of (b)(4) or (b)(4) to inspect features during in-process and final inspections for which there are no documented rationales for use of these sampling plans. For example, out of (b)(4) ELEOS Segmental Proximal Femur, Plasma Spray, Left 98 MM (Part # PF-2000L-02M) Implant Devices, the dimensional specification of (b)(4) was inspected at an AQL level of (b)(4) for Lot # (b)(4) during final inspection on 1\u002F23\u002F24.\nWe reviewed your firm’s response and concluded that it is not adequate. The immediate corrections are to use a checklist to reassess and document rationales for acceptability of the existing AQLs selected for all contract manufactured ELEOS part families from 1\u002F1\u002F21 to 4\u002F1\u002F25 and share the rationales with the contract manufacturers by 11\u002F21\u002F25 and update SCAR 25-01 to require the contract manufacturer to include documented evidence for all inspected dimensions and associated AQL quantities by 5\u002F14\u002F25. As a part of the corrective actions, you plan to update SOP-014 and WI-013-31 (Incoming Inspection Process) to require review of incoming inspection results, consolidation of sampling procedures, set up traceable valid statistical rationales, and confirm AQLs by 7\u002F6\u002F25; update SOP-007 (Design Control) and various design transfer, manufacturing transfer, supplier, and incoming inspection checklists to include instructions for the acceptance of a supplier’s sampling procedure with confirmation of conformance to those procedures during incoming inspection of supplier DHRs by (b)(4); and develop (b)(4) inspection requirement checklists for all suppliers with a sampling procedure traceable to a valid statistical rationale based on (b)(4) by 7\u002F18\u002F25. However, these corrections and\u002For corrective actions only address the need to have a statistically valid rationale for the use of sampling plans which follow AQL and not sampling plans which utilize inspections of select critical features for the (b)(4) devices. Therefore, please provide a response on how you plan to address the above deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\nCorrections and Removals Violation(s)\nOur inspection also revealed that your firm’s ELEOS Limb Salvage System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n5. Failure to submit a medical device Report of Correction or Removal for an action initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR Part 806.10. For example:\na. Your firm conducted a removal of numerous part numbers and lot numbers of your ELEOS Limb Salvage System due to sterile packaging separation and damaged trays, which can result in extended surgery time or potential patient infection. Your firm sent a Customer Notification for this issue on 6\u002F28\u002F2023. This action meets the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nb. On or about 10\u002F15\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Male-Female Midsection 40MM, due to taper post misalignment, which can result in extended surgery time or improperly assembled devices leading to future disassociation. Your firm sent a Customer Notification for this issue dated 9\u002F20\u002F2024. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nc. On or about 1\u002F22\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Collar Stem, Cemented, Fluted 13MM X 120MM and Collar Stem, Cemented, Fluted 15MM X 120MM due to mislabeling of the devices, which can result in implantation or attempted implantation of an incorrect stem size, potentially extending surgery time or causing the patient to need revision surgery. Your firm sent a Customer Notification for this issue on 12\u002F22\u002F2023. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nThe adequacy of your firm’s response, dated 5\u002F14\u002F2025, regarding Observation 5 cannot be determined because we do not have assurance that your firm will make appropriate decisions following 21 CFR 806 in the future, based on your firm’s root cause stating that your firm’s SOP is ambiguous and subjective. Your firm adequately reported by retroactively submitting Reports of Correction or Removal to FDA addressing each of the three issues on 4\u002F25\u002F2025.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 712573” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Len Tokish\nVP of Quality Assurance & Regulatory Affairs\nltokish@onkossurgical.com","Onkos Surgical, Inc.","onkos-surgical-inc-712573-07212025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonkos-surgical-inc-712573-07212025","2026-10-26T08:09:38.140644+00:00","2025-07-29","712573","Patrick J. Treacy","2026-08-19T16:32:45.913+00:00","2025-07-21",{"id":189,"raw":190,"subject":194,"body_html":195,"body_text":196,"firm_name":197,"letter_id":198,"created_at":18,"fei_number":19,"letter_url":199,"updated_at":200,"action_type":22,"case_status":23,"posted_date":201,"marcs_cms_no":202,"product_type":203,"closeout_date":19,"issuing_office":100,"recipient_name":204,"body_fetched_at":205,"delivery_method":206,"recipient_title":19,"reference_number":19,"action_taken_date":207,"medical_device_id":19,"response_letter_date":19},234,[191,192,193,100,194,13,13,13],"\u003Ctime datetime=\"2026-04-14T04:00:00Z\">04\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-09T04:00:00Z\">04\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-products-laboratories-inc-721916-04092026\">Medical Products Laboratories, Inc.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Elliot Stone\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medical Products Laboratories, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9990 Global Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Philadelphia\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19115\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-61\u003C\u002Fp>\u003Cp>April 9, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Stone:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Medical Products Laboratories, Inc., FEI 2513595, at 9990 Global Road, Philadelphia, from September 29 to October 16, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Your firm manufactures and is responsible for introducing or delivering for introduction into interstate commerce in the United States products that are unapproved new drugs in violation of sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. Sections 331(d) and 355(a), including but not limited to: Hydro-Q 4% Gel (hydroquinone 4%); Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension; Sodium Sulfacetamide 9% and Sulfur 4% Wash; Sodium Sulfacetamide 9.8% Shampoo; Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser; Sodium Sulfacetamide 9.8% and Sulfur 4.8% Lotion; Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cream; Sodium Sulfacetamide 10% and Sulfur 5% Cleanser; Sodium Sulfacetamide 10% Wash; Salicylic Acid 28.5% Solution; Plexion Shampoo (sodium sulfacetamide 9.8%); Plexion Lotion (sodium sulfacetamide 9.8% and sulfur 4.8%), Plexion Cream (sodium sulfacetamide 9.8% and sulfur 4.8%) as prescription drug products. Based on our review, these products are unapproved new drugs under section 505(a) of the FD&amp;C Act, 21 U.S.C. Section 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. Sections 331(d) and 355(a).\u003C\u002Fp>\u003Cp>We reviewed your November 6, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures, designed to prevent objectionable microorganisms in drug products not required to be sterile (21 CFR 211.113(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Microbiological Results in Finished Drug Product and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Samples\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm manufactures prescription and over-the-counter (OTC) drug products for \u003Cstrong>(b)(4)\u003C\u002Fstrong> administration. You failed to adequately establish and follow procedures to prevent contamination with objectionable microorganisms. For example, you used an unvalidated \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment protocol on filled drug product batches in an attempt to reduce microbiological content. Your laboratory reported gross microbiological contamination on plates for both total aerobic microbiological count (TAMC) and total yeast and mold count (TYMC) tests in the following non-sterile finished drug products for \u003Cstrong>(b)(4)\u003C\u002Fstrong> administration:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (TAMC: too numerous to count (TNTC) and TYMC: TNTC)\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (TAMC: TNTC and TYMC: TNTC)\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (TAMC: TNTC and TYMC: \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFU) per gram)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your investigation of the failing results in \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> concluded that contamination was from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> component, recovered from a mixture of this component with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your investigation failed to consider out-of-limit (OOL) microbiological recoveries from your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003C\u002Fp>\u003Cp>You subsequently released drug products based on results from \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment resampling. Your corrective action and preventive action (CAPA) in response to the microbiological contamination included revising the drug product formulation to increase \u003Cstrong>(b)(4)\u003C\u002Fstrong> content. \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not a substitute for a comprehensive approach to preventing objectionable microorganisms from contaminating your drug products and cannot be relied on to reduce in-process bioburden during manufacturing.\u003C\u002Fp>\u003Cp>We note that on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you issued a voluntary recall of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lots \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to microbiological contamination.\u003C\u002Fp>\u003Cp>Your response commits to revising your procedures to no longer allow \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment to rework batches after failing microbiological results and to place a reworked batch on real-time stability. You also include a risk assessment which concludes there is no health risk for two failing lots. Your response is inadequate in that your risk assessment does not extend to all drug products where \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment was attempted, nor does your response provide your plans for addressing product quality and patient safety risks for lots on which you used \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment or product you released after failing microbiological results. Moreover, your response does not address whether additional bacterial species were present, nor did you provide evidence supporting your claims that growth on total yeast and mold plates was solely bacterial.\u003C\u002Fp>\u003Cp>This adverse pattern of microbiological contamination in your drug products demonstrates a significant failure to adhere to CGMP. Unresolved manufacturing and quality problems can pose a significant hazard to patients.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>Complete investigations into all batches with potential objectionable microbiological contamination or a failing microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\u003Cli>Appropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\u003C\u002Fli>\u003Cli>A summary of results from testing retain samples of all drug product batches of which you have received failing, out-of-specification (OOS), OOL or out-of-trend (OOT) microbiological test results. Also provide test results of retains during periods when your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system was not operating under a state of control. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields any failing, OOS or OOL result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fli>\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003Cbr>o Provide a comprehensive evaluation of vulnerabilities of \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design and control, and summarize all deficiencies found in the system. The summary should, at minimum, describe various system characteristics that were assessed for adequacy (system temperature, materials of construction, slope, any identified dead-legs, any stagnant locations, any unsanitary fittings, flow velocity, etc.)\u003C\u002Fli>\u003Cli>Your total microbiological count limits to monitor whether this system is producing \u003Cstrong>(b)(4)\u003C\u002Fstrong> suitable for the intended uses for each of your products.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> system failures on the quality of all drug product lots currently within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately validate your manufacturing processes to demonstrate that your processes are reproducible and controlled to consistently yield drug products of uniform character and quality. For example, you used a process qualification study performed at a different facility to manufacture and release \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You could not provide evidence your processes (e.g. equipment, components, and manufacturing conditions) were comparable between your facility and the site where initial process validation was performed.\u003C\u002Fp>\u003Cp>Additionally, you failed to adequately validate your process for manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong>. While a process validation study for this product had been initiated, it included insufficient data. At the direction of your customer, you discontinued your efforts to complete process validation for this product, yet you continued manufacturing batches for commercial distribution.\u003C\u002Fp>\u003Cp>In your response, you discuss a retrospective review of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches within expiry. You also indicate that you have paused production of \u003Cstrong>(b)(4)\u003C\u002Fstrong> until process validation activities can be completed. You also state that you have updated your process validation procedure and that you have verified that process validation studies have been conducted for drug products you manufacture. Your response is inadequate in that you did not evaluate the implications of changes made to product formulations for drug products that you manufacture.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products which lack appropriate studies. Also include an explanation how you will ensure proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\u003C\u002Fli>\u003Cli>A risk assessment for the distributed drug products produced without performing any process validation studies or using inadequately validated processes.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program, including your procedure, for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Finished Drug Product Microbiological Testing\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm failed to adequately investigate failing microbiological results in finished products. For example, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> obtained a failing result of \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fg for TYMC (specification ≤\u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fg). After your contract testing laboratory failed to identify the fungal species, you concluded, without evidence, that contamination occurred “during handling, transportation and\u002For testing.” You invalidated this failing result based on results of resampling and released the lot.\u003C\u002Fp>\u003Cp>Microbiological contamination may not be uniformly distributed. A product sample may not be representative of the type or level of contamination within the batch. Further, testing the final product for microbiological contamination does not ensure that you have appropriate controls in place to ensure product quality. As a manufacturer, you have a responsibility to fully investigate unexplained discrepancies, deviations, and failures to assess their impact on product quality.\u003C\u002Fp>\u003Cp>\u003Cem>Stability Assay\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm failed to conduct adequate investigations into OOS stability results. For example, in two separate incidents, you invalidated OOS stability results for subpotent assay without adequate scientific justification. You relied on resampling data from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lots \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to invalidate the initial stability OOS result with no identified laboratory error or rationale.\u003C\u002Fp>\u003Cp>\u003Cem>Complaint Investigations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You did not adequately investigate complaints you received. For example, upon receiving complaints of product crystallization in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you concluded that this crystallization was due to “transportation and\u002For storage” during winter months. Your investigation failed to consider changes made to the formulation or the status of process validation activities for the formulation.\u003C\u002Fp>\u003Cp>In your response, you commit to reopening complaints of crystallization and discoloration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> while pausing manufacturing of this product. You also commit to revising your complaint and investigation procedures, but you did not provide revised procedures. Your response also fails to perform a retrospective review of invalidated OOS results or discuss improperly invalidated results for drug products which remain on the market.\u003C\u002Fp>\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A retrospective, independent review of all invalidated failing\u002FOOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated failing\u002FOOS results conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all failing\u002FOOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your failing\u002FOOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequately scoping of each investigation and its CAPA\u003Cbr>o Revised failing\u002FOOS investigation procedures with these and other remediations\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your stability program was not adequate to ensure that the drug products you manufacture, maintain their identity, strength, quality, purity, and safety throughout their shelf lives. For example, your stability study for \u003Cstrong>(b)(4)\u003C\u002Fstrong> concluded that a \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration is supported at a temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Celsius (\u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Fahrenheit). However, your firm labeled much wider storage conditions as \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Fahrenheit at the instruction of your customer, without adequate data to support the wider labeled storage conditions. We note that you reduced the range of the labeled temperature limits, but they were still outside the range of your stability data.\u003C\u002Fp>\u003Cp>In your response, you committed to revising the stability protocol for this product and placing future lots on stability. You also state that you “can no longer rely on written justifications from product owners to deviate from the general [C]GMP requirements.” Your response is inadequate in that you do not include a comprehensive review of your stability program, nor do you provide your revised stability protocol. Additionally, your response does not describe a retrospective review of batches which lack adequate stability data to support labeled expiration dates and storage conditions.\u003C\u002Fp>\u003Cp>Without the appropriate stability studies, you do not have adequate scientific evidence to support that your drug product retains its quality attributes throughout the labeled \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiry period.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o A detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s products are drugs as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. Section 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from your product labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>Hydro-Q Gel (hydroquinone 4%)\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines and areas of melanin hyperpigmentation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Plexion Shampoo (sodium sulfacetamide 9.8%)\u003C\u002Fp>\u003Cul>\u003Cli>Intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Plexion Cream and Plexion Lotion (sodium sulfacetamide 9.8%, sulfur 4.8%)\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Sodium Sulfacetamide 9.8% Shampoo\u003C\u002Fp>\u003Cul>\u003Cli>Intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Sodium Sulfacetamide 10% Wash\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cream, Cleanser, and Lotion\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Sodium Sulfacetamide 9% and Sulfur 4% Wash\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Sodium Sulfacetamide 10% and Sulfur 5% Cleanser\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Salicylic Acid 28.5% Solution\u003C\u002Fp>\u003Cul>\u003Cli>Indicated for the topical treatment and removal of common warts and plantar warts.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling.\u003C\u002Fp>\u003Cp>With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products.\u003C\u002Fp>\u003Cp>Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You and your customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have a quality agreement regarding the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: \u003Cem>Q8(R2) Pharmaceutical Development\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, \u003Cem>Q9(R1) Quality Risk Management\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and \u003Cem>Q10 Pharmaceutical Quality System\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>FDA requests that you contact CDER's Drug Shortages Staff immediately at drugshortages@fda.hhs.gov so that we can work with you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture, as required under 21 U.S.C.§ 356c(a), and to allow FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who use your products.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2513595 and ATTN: Andrew Haack.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Elliot Stone\n\nRecipient Title\n\nPresident\u002FCEO\n\nMedical Products Laboratories, Inc.\n\n9990 Global Road\n\nPhiladelphia, PA 19115\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-61\nApril 9, 2026\nDear Mr. Stone:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Medical Products Laboratories, Inc., FEI 2513595, at 9990 Global Road, Philadelphia, from September 29 to October 16, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nYour firm manufactures and is responsible for introducing or delivering for introduction into interstate commerce in the United States products that are unapproved new drugs in violation of sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. Sections 331(d) and 355(a), including but not limited to: Hydro-Q 4% Gel (hydroquinone 4%); Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension; Sodium Sulfacetamide 9% and Sulfur 4% Wash; Sodium Sulfacetamide 9.8% Shampoo; Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser; Sodium Sulfacetamide 9.8% and Sulfur 4.8% Lotion; Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cream; Sodium Sulfacetamide 10% and Sulfur 5% Cleanser; Sodium Sulfacetamide 10% Wash; Salicylic Acid 28.5% Solution; Plexion Shampoo (sodium sulfacetamide 9.8%); Plexion Lotion (sodium sulfacetamide 9.8% and sulfur 4.8%), Plexion Cream (sodium sulfacetamide 9.8% and sulfur 4.8%) as prescription drug products. Based on our review, these products are unapproved new drugs under section 505(a) of the FD&C Act, 21 U.S.C. Section 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. Sections 331(d) and 355(a).\nWe reviewed your November 6, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\nCGMP Violations\n1. Your firm failed to establish and follow appropriate written procedures, designed to prevent objectionable microorganisms in drug products not required to be sterile (21 CFR 211.113(a)).\nMicrobiological Results in Finished Drug Product and (b)(4) Samples\nYour firm manufactures prescription and over-the-counter (OTC) drug products for (b)(4) administration. You failed to adequately establish and follow procedures to prevent contamination with objectionable microorganisms. For example, you used an unvalidated (b)(4) treatment protocol on filled drug product batches in an attempt to reduce microbiological content. Your laboratory reported gross microbiological contamination on plates for both total aerobic microbiological count (TAMC) and total yeast and mold count (TYMC) tests in the following non-sterile finished drug products for (b)(4) administration:\n(b)(4) lot (b)(4) (TAMC: too numerous to count (TNTC) and TYMC: TNTC)\n(b)(4) lot (b)(4) (TAMC: TNTC and TYMC: TNTC)\n(b)(4) lot (b)(4) (TAMC: TNTC and TYMC: (b)(4) colony forming units (CFU) per gram)\nYour investigation of the failing results in (b)(4) lot (b)(4) concluded that contamination was from the (b)(4) component, recovered from a mixture of this component with (b)(4). However, your investigation failed to consider out-of-limit (OOL) microbiological recoveries from your (b)(4) system.\nYou subsequently released drug products based on results from (b)(4) treatment resampling. Your corrective action and preventive action (CAPA) in response to the microbiological contamination included revising the drug product formulation to increase (b)(4) content. (b)(4) are not a substitute for a comprehensive approach to preventing objectionable microorganisms from contaminating your drug products and cannot be relied on to reduce in-process bioburden during manufacturing.\nWe note that on (b)(4), you issued a voluntary recall of (b)(4), lots (b)(4), due to microbiological contamination.\nYour response commits to revising your procedures to no longer allow (b)(4) treatment to rework batches after failing microbiological results and to place a reworked batch on real-time stability. You also include a risk assessment which concludes there is no health risk for two failing lots. Your response is inadequate in that your risk assessment does not extend to all drug products where (b)(4) treatment was attempted, nor does your response provide your plans for addressing product quality and patient safety risks for lots on which you used (b)(4) treatment or product you released after failing microbiological results. Moreover, your response does not address whether additional bacterial species were present, nor did you provide evidence supporting your claims that growth on total yeast and mold plates was solely bacterial.\nThis adverse pattern of microbiological contamination in your drug products demonstrates a significant failure to adhere to CGMP. Unresolved manufacturing and quality problems can pose a significant hazard to patients.\nIn response to this letter, provide:\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nComplete investigations into all batches with potential objectionable microbiological contamination or a failing microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\nAppropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\nA summary of results from testing retain samples of all drug product batches of which you have received failing, out-of-specification (OOS), OOL or out-of-trend (OOT) microbiological test results. Also provide test results of retains during periods when your (b)(4) system was not operating under a state of control. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields any failing, OOS or OOL result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\nA comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system.\no Provide a comprehensive evaluation of vulnerabilities of (b)(4) system design and control, and summarize all deficiencies found in the system. The summary should, at minimum, describe various system characteristics that were assessed for adequacy (system temperature, materials of construction, slope, any identified dead-legs, any stagnant locations, any unsanitary fittings, flow velocity, etc.)\nYour total microbiological count limits to monitor whether this system is producing (b)(4) suitable for the intended uses for each of your products.\nA detailed risk assessment addressing the potential effects of the observed (b)(4) system failures on the quality of all drug product lots currently within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYou failed to adequately validate your manufacturing processes to demonstrate that your processes are reproducible and controlled to consistently yield drug products of uniform character and quality. For example, you used a process qualification study performed at a different facility to manufacture and release (b)(4). You could not provide evidence your processes (e.g. equipment, components, and manufacturing conditions) were comparable between your facility and the site where initial process validation was performed.\nAdditionally, you failed to adequately validate your process for manufacturing (b)(4). While a process validation study for this product had been initiated, it included insufficient data. At the direction of your customer, you discontinued your efforts to complete process validation for this product, yet you continued manufacturing batches for commercial distribution.\nIn your response, you discuss a retrospective review of (b)(4) batches within expiry. You also indicate that you have paused production of (b)(4) until process validation activities can be completed. You also state that you have updated your process validation procedure and that you have verified that process validation studies have been conducted for drug products you manufacture. Your response is inadequate in that you did not evaluate the implications of changes made to product formulations for drug products that you manufacture.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate PPQ for each of your marketed drug products which lack appropriate studies. Also include an explanation how you will ensure proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\nA risk assessment for the distributed drug products produced without performing any process validation studies or using inadequately validated processes.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program, including your procedure, for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nFinished Drug Product Microbiological Testing\nYour firm failed to adequately investigate failing microbiological results in finished products. For example, your (b)(4) lot (b)(4) obtained a failing result of (b)(4) CFU\u002Fg for TYMC (specification ≤(b)(4) CFU\u002Fg). After your contract testing laboratory failed to identify the fungal species, you concluded, without evidence, that contamination occurred “during handling, transportation and\u002For testing.” You invalidated this failing result based on results of resampling and released the lot.\nMicrobiological contamination may not be uniformly distributed. A product sample may not be representative of the type or level of contamination within the batch. Further, testing the final product for microbiological contamination does not ensure that you have appropriate controls in place to ensure product quality. As a manufacturer, you have a responsibility to fully investigate unexplained discrepancies, deviations, and failures to assess their impact on product quality.\nStability Assay\nYour firm failed to conduct adequate investigations into OOS stability results. For example, in two separate incidents, you invalidated OOS stability results for subpotent assay without adequate scientific justification. You relied on resampling data from (b)(4), lots (b)(4), to invalidate the initial stability OOS result with no identified laboratory error or rationale.\nComplaint Investigations\nYou did not adequately investigate complaints you received. For example, upon receiving complaints of product crystallization in (b)(4), you concluded that this crystallization was due to “transportation and\u002For storage” during winter months. Your investigation failed to consider changes made to the formulation or the status of process validation activities for the formulation.\nIn your response, you commit to reopening complaints of crystallization and discoloration of (b)(4) while pausing manufacturing of this product. You also commit to revising your complaint and investigation procedures, but you did not provide revised procedures. Your response also fails to perform a retrospective review of invalidated OOS results or discuss improperly invalidated results for drug products which remain on the market.\nInadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA retrospective, independent review of all invalidated failing\u002FOOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated failing\u002FOOS results conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all failing\u002FOOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nA comprehensive review and remediation plan for your failing\u002FOOS result investigation systems. The CAPA should include but not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequately scoping of each investigation and its CAPA\no Revised failing\u002FOOS investigation procedures with these and other remediations\n4. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nYour stability program was not adequate to ensure that the drug products you manufacture, maintain their identity, strength, quality, purity, and safety throughout their shelf lives. For example, your stability study for (b)(4) concluded that a (b)(4) expiration is supported at a temperature of (b)(4) to (b)(4) degrees Celsius ((b)(4) to (b)(4) degrees Fahrenheit). However, your firm labeled much wider storage conditions as (b)(4) to (b)(4) degrees Fahrenheit at the instruction of your customer, without adequate data to support the wider labeled storage conditions. We note that you reduced the range of the labeled temperature limits, but they were still outside the range of your stability data.\nIn your response, you committed to revising the stability protocol for this product and placing future lots on stability. You also state that you “can no longer rely on written justifications from product owners to deviate from the general [C]GMP requirements.” Your response is inadequate in that you do not include a comprehensive review of your stability program, nor do you provide your revised stability protocol. Additionally, your response does not describe a retrospective review of batches which lack adequate stability data to support labeled expiration dates and storage conditions.\nWithout the appropriate stability studies, you do not have adequate scientific evidence to support that your drug product retains its quality attributes throughout the labeled (b)(4) expiry period.\nIn response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no A detailed definition of the specific attributes to be tested at each station (timepoint)\no All procedures that describe these and other elements of your remediated stability program.\nUnapproved New Drug Violations\nYour firm’s products are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. Section 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\nExamples from your product labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nHydro-Q Gel (hydroquinone 4%)\nIndicated for the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines and areas of melanin hyperpigmentation.\nPlexion Shampoo (sodium sulfacetamide 9.8%)\nIntended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff).\nPlexion Cream and Plexion Lotion (sodium sulfacetamide 9.8%, sulfur 4.8%)\nIndicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\nSodium Sulfacetamide 9.8% Shampoo\nIntended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff).\nSodium Sulfacetamide 10% Wash\nIndicated for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.\nSodium Sulfacetamide 9.8% and Sulfur 4.8% Cream, Cleanser, and Lotion\nIndicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\nSodium Sulfacetamide 8% and Sulfur 4% Topical Suspension\nIndicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\nSodium Sulfacetamide 9% and Sulfur 4% Wash\nIndicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\nSodium Sulfacetamide 10% and Sulfur 5% Cleanser\nIndicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.\nSalicylic Acid 28.5% Solution\nIndicated for the topical treatment and removal of common warts and plantar warts.\nYour products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling.\nWith certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products.\nAccordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou and your customer (b)(4), have a quality agreement regarding the manufacture of (b)(4). You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nQuality Systems\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, Q9(R1) Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\nConsultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nFDA requests that you contact CDER's Drug Shortages Staff immediately at drugshortages@fda.hhs.gov so that we can work with you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture, as required under 21 U.S.C.§ 356c(a), and to allow FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who use your products.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2513595 and ATTN: Andrew Haack.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Medical Products Laboratories, Inc.","medical-products-laboratories-inc-721916-04092026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-products-laboratories-inc-721916-04092026","2026-10-26T08:09:23.057513+00:00","2026-04-14","721916","Drugs","Mr. Elliot Stone","2026-08-19T04:47:49.417+00:00","VIA UPS","2026-04-09",10,{"510k":210,"classification":211,"enforcement":212,"event":213,"event_backfill":214,"pma":215,"warning_letter":216},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]